RELATIVE VALUATION OF BANGKOK CHAIN HOSPITAL PUBLIC COMPANY LIMITED




A THEMATIC PAPER SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF MANAGEMENT COLLEGE OF MANAGEMENT MAHIDOL UNIVERSITY 2018

COPYRIGHT OF MAHIDOL UNIVERSITY

Thematic paper entitled

RELATIVE VALUATION OF BANGKOK CHAIN HOSPITAL PUBLIC COMPANY LIMITED (BCH)

was submitted to the College of Management, Mahidol University for the degree of Master of Management on December 23, 2018



ACKNOWLEDGEMENTS

First of all, I would like to express my sincerest gratitude to all of my professors at CMMU who instruct me well on management and financial knowledge which enhance me to open overall business view and deeply understand about financial management both on business and capital market view. All of my professors are always welcomed as a good instructor and consultant. Most importantly, their knowledges and advices passing on to me throughout my study period were extremely important for this thematic paper to be completed.

Last but not the least, I would like to give all my success to my family who have been my spirit and given moral support during my time here. Their support influence me to be successful. I hope that this success will make them proud.

Chanwit Ritkriengkrai

RELATIVE VALUATION OF BANGKOK CHAIN HOSPITAL PUBLIC COMPANY LIMITED

CHANWIT RITKRIENGKRAI 6049091

M.M. (FINANCIAL MANAGEMENT)

THEMATIC PAPER ADVISORY COMMITTEE: SIMON M. ZABY, Ph.D., ASSOC.PROF. TATRE JANTARAKOLICA, Ph.D., ASST. PROF. PIYAPAS THARAVANIJ, Ph.D.

ABSTRACT

This thematic paper intends to value the stock price of Bangkok Chain Hospital Public Company Limited (BCH) base on relative valuation method which represent the concept of comparing a company's value to that of its competitors or industry peers to assess the firm's financial worth. Considering with upside in Thailand's healthy trend and rising in aging society as well as monthly income per household, these factors enhance BCH opportunity to grow in both domestic and international especially for CLMV countries. The target price of year ended 2018 of BCH shall approximately equal to 20.22 Baht per share with 15% upside from the current price of 17.50 Baht per share on 20 November 2018. Therefore, the valuation is indicative to BUY. In addition, BCH has strong profit from core operation. The expansion in Greenfield project will increase in capacity to support more patients. Moreover the rising performance of World medical center support the performance of BCH. In conclusion, the valuation study suggest company intrinsic value which the method still has some limitations. Therefore, the value must be looked carefully. However, the study can still provide guidance regarding intrinsic valuation for investors and interested person in health care companies.

KEY WORDS: BCH / Valuation / Relative Valuation / Hospital

68 pages

CONTENTS

		Page
ACKNOWLEI	OGEMENTS	ii
ABSTRACT		iii
LIST OF TAB	LES	viii
LIST OF FIGU	JRES	X
LIST OF ABB	REVIATIONS	xii
CHAPTER I	VALUATION	1
1.1	Highlights	1
	1.1.1 Solid Performance from growth strategies	1
	1.1.2 Growth from performance of WMC	3
	1.1.3 Growth from expansion new hospitals	3
	1.1.4 Secured recurring income from social security scheme	3
	1.1.5 Macro environment favors to BCH	4
1.2	Business Description	4
	1.2.1 Business	4
	1.2.2 Revenue	5
	1.2.3 Services and brands	7
	1.2.4 Management and Administration	9
	1.2.5 Strategies	11
	1.2.6 Corporate Governance	12
1.3	Macro-Economic Analysis	13
	1.3.1 Private hospital in nutshell	13
	1.3.2 Health expenditures is lower than other countries	14
	1.3.3 Income and health expenditure	15
	1.3.4 Aging population	15

CONTENTS (cont.)

		Page
1.4	Industry Analysis	16
	1.4.1 Asia healthcare medical hub	17
	1.4.2 Digital Innovation integrated in healthcare	17
	1.4.3 Health awareness	18
	1.4.4 Medical tourism	18
1.5	Competition Analysis	19
1.6	Financial Statement Analysis	25
	1.6.1 Trend Analysis	32
	1.6.2 Financial Ratio: Return	34
	1.6.3 Financial Ratio: Risk	35
	1.6.4 Forecast Financial ratio 2018-2022	37
	1.6.4.1 Profitability margins improve by solid operations	37
	1.6.4.2 Stronger financial ratio for return and risk ratios	37
1.7	Investment Summary	38
	1.7.1 Profit will hit new high record in 2019	38
	1.7.2 Rising of World Medical Center (WMC) performance	38
	1.7.3 Open new hospitals in Q4 2018 and next three years	39
1.8	Valuation	39
	1.8.1 Pro Forma analysis	39
	1.8.1.1 Segmentation	39
	1.8.1.2 Quantity	40
	1.8.1.3 Price	44
	1.8.1.4 Cost from hospital operation	46
	1.8.2 Relative valuation	47

CONTENTS (cont.)

		Page
	1.8.2.1 Ratio bands	47
	1.8.2.2 Group of peers	50
	1.8.2.3 Valuation estimation	51
	1.8.2.4 Valuation recommendation	52
	1.8.2.5 Rating criteria	53
	1.8.2.6 Sensitivity analysis	53
1.9	Investment Risks and Downside Possibilities	54
	1.9.1 The competition in private hospital industry	54
	1.9.2 Limitation of the numbers of expertise	54
	1.9.3 The regulatory changes on managed care programs	55
	1.9.4 Economic downturn	56
	1.9.5 The consumer behavior	56
	1.9.6 High Working capital and CAPEX	56
	1.9.7 Scenario analysis	57
CHAPTER II	DATA	60
2.1	Financial statement analysis	63
	2.1.1 Trend Analysis	60
	2.1.2 Common size	61
	2.1.3 Growth analysis	63
2.2	Information	65
	2.2.1 Business Structure	65
	2.2.2 Major shareholders	66
	2.2.3 Management and organizational chart	66

CONTENTS (cont.)

	Page
2.2.4 Patients referral network	66
REFERENCES	67
BIOGRAPHY	68



LIST OF TABLES

Table		Page
1.1	Market profile	1
1.2	BCH's Key Financial Ratios	2
1.3	BCH's Revenue 2017 - Breakdown by type of patients	7
1.4	Revenue by brands in 2017	8
1.5	Price and procedure comparison	19
1.6	Profit / (Loss) - Compare with Peer	25
1.7	BCH's Statement of financial position	28
1.8	VIBHA's Statement of financial position	29
1.9	Summary of Cash flow - Compare with Peer	31
1.10	BCH's financial ratio – Return	34
1.11	VIBHA's financial ratio – Return	34
1.12	BCH's financial ratio – Risk	35
1.13	VIBHA's financial ratio – Risk	36
1.14	BCH's forecast financial ratio 2018-2022	37
1.15	Revenue by segments	40
1.16	Quantity of WMC	41
1.17	Quantity of KH & KV	43
1.18	Price of WMC	44
1.19	Price of KH & KV	45
1.20	BCH's Forecast revenue from hospital operation	46
1.21	BCH's Forecast cost from hospital operation	47
1.22	Estimate target price from Forward EV/EBITDA band	50
1.23	BCH's comparable firms and their ratios	51
1.24	Pro-forma	51
1.25	Relative valuation summary	52

LIST OF TABLES (cont.)

Table		Page
1.26	Rating criteria	53
1.27	Sensitivity analysis - EBITDA	53
1.28	Sensitivity Spider Chart	58
1.29	Scenario Analysis for Revenue	58
1.30	Scenario Analysis for Cost	59
2.1	Trend Analysis	60
2.2	Common Size	61
2.3	Growth analysis	63

LIST OF FIGURES

Figure		Page
1.1	BCH's EPS and Return	2
1.2	Utilization rate of IPD: Beds day	5
1.3	ROA	5
1.4	BCH's Revenue 2017 - Breakdown by type of patients	7
1.5	Revenue by brands in 2017	8
1.6	IPD-Utilization rate per year	10
1.7	OPD-Utilization rate per year	10
1.8	SS-CAGR Numbers of registered persons	10
1.9	Monthly Income Per Household	14
1.10	% of Healthcare expenditure to GDP	14
1.11	Number of ICU beds per million population	15
1.12	Age pyramid in 2017 and 2030	16
1.13	Competitiveness of Thai Private Hospital vs. Other in ASEAN	17
1.14	Trend of Medical tourist to Thailand	19
1.15	Revenue 2017 - Breakdown by private hospitals	20
1.16	Market Capital 2017 - Breakdown by private hospitals	20
1.17	Pricing comparison	23
1.18	Five force analysis of BCH	23
1.19	Revenue of hospital operations - Compare with Peer	26
1.20	Cost of hospital operations - Compare with Peer	26
1.21	Net income - Compare with Peer	27
1.22	Profit and Loss Trend	32
1.23	Financial position Trend	33
1.24	Quantity of WMC - OPD	41
1.25	Quantity of WMC - IPD	42

LIST OF FIGURES (cont.)

Figure		Page
1.26	Quantity of KH & KV -OPD	43
1.27	Quantity of KH & KV - IPD	43
1.28	Quantity of KH & KV - SS	44
1.29	Price of WMC	45
1.30	Price of KH & KV	46
1.31	Trailing P/E band	48
1.32	Forward P/E band	48
1.33	Trailing PBV band	49
1.34	Forward PBV band	49
1.35	Trailing EV/EBITDA band	49
1.36	Forward EV/EBITDA band	50
1.37	Risk matrix	54
1.38	Healthcare supply in Thailand	55
1.39	Sensitivity spider chart	58
2.1	Shareholding structure of the company	65
2.2	Shareholders	65
2.3	Organization chart	66
2.4	Patients referral network	66

LIST OF ABBREVIATIONS

CAGR Compound Annual Growth Rate

CAPM Capital Asset Pricing Model

CAPEX Capital Expenditure

COGS Cost of Goods Sold

DCF Discounted Cash Flow

D/E Debt/Equity

EBIT Earnings before Interest and Taxes

EBITDA Earnings before Interest, Taxes and Depreciation

EPS Earnings per share

GDP Gross Domestic Product

IPD In-Patient

NOPAT Net Operating Profit after Taxes

NOWC Net Operating Working Capital

OPD Out-Patient

Rf Risk free

ROA Return on Assets

ROE Return on Equity

SET Stock Exchange of Thailand

SG&A Selling, General and Administrative Expense

SS Social Security Patient

SSO Social Security Office

WACC Weighted Average Cost of Capital

YOY Year on Year

CHAPTER I VALUATION

1.1 Highlight of BCH valuation

The recommendation is BUY for Bangkok Chain Hospital Public Co. Ltd. with a target price of THB 20.22 applying the relative valuation method. Its offer 15% upside from its closing price of THB 17.5 on November 20, 2018. BCH has the opportunities to grow from its core business of revenues from hospital operation with a solid performance, growth from performance of WMC, growth from expansion new hospitals and secured recurring income from social security scheme. Moreover, the macro environment favors to BCH is the factor that enable BCH to grow.

Table 1.1 Market profile

Market Profile					
Closing Price	THB 17.5				
52-Week Price Range	14.90 - 21.10				
Average Daily	183.26 M				
Share Outstanding	2493.75 M				
Market Cap.	43,640 M				
Dividend Yield	1.05%				
Trailing P/E	39.7				
Forward P/E	40.3				
P/BV	8				
ROE	18.42%				
EPS	THB 0.37				
Dividend per share	THB 0.20				
Book value per share	THB 2.47				

1.1.1 Solid Performance from growth strategies

BCH can maintain the higher performance as reflecting in its historical financial statement because of its strategies. The main strategies consist of strong brands, expansion and customer. The company also has the strategic plan to increasing revenue growth and net profit margin by four strategies of the enhancement of internal

process of hospitals' facilities, the upgrade of hospitals in the strategic locations to be the patients referral centers, business expansion both local and international through the construction of new hospitals and strategic acquisitions and rebranding of existing hospital in order to capture more market segmentation. The overall strategies could support the solid performance of BCH as well as increase in efficiency controlling of its cost over the years. Referring to the BCH's key financial ratios as below figure, gross margin and net profit margin increase over the years. The turnover ratios as total assets turnover, ROA and ROE also raise over the years that indicate the solid performance. In addition, the current ratio is quite high and interest bearing debt to equity is lower than 1. The EPS of BCH also increase over the years from 0.23 in 2013 to 0.37 in 2017 as below figure. Moreover, BCH share price also continuously raises from year 2015 until now.



Figure 1.1 BCH's EPS and Return

Table 1.2 BCH's Key Financial Ratios

Key Ratios	2017	2016	2015	2014	2013
Gross Margin	33%	31%	31%	31%	32%
Net Profit Margin	15%	14%	12%	13%	15%
Total Asset Turnover	0.62	0.62	0.56	0.53	0.55
Return on Asset	10.80%	10.35%	8.12%	8.30%	9.65%
Return on Equity	20.32%	18.69%	14.62%	15.12%	17.19%
Current Ratio	1.48	0.74	0.70	1.07	1.25
Interest-bearing Debt to Equity	0.93	0.77	0.93	0.90	0.93

1.1.2 Growth from performance of WMC

WMC performance will dramatically increase in 2018 because of higher in the number of international patients. Especially in second half year of 2018, the OPD utilization increase by 26% and IPD utilization increase by 84%. The factor that help to enhance the number of patients comes from working with agents to attract the international patients. The performance of WMC would be increasing over the years from the strategies of BCH to attract the new potential patients. The better performance of WMC would support the overall performance of BCH.

1.1.3 Growth from expansion new hospitals

The company increase their new hospital in the strategic location. It is the zone of target customers and far from their competitors. From the Analyst Presentation in March 2018, the five more hospital branches both locally and internationally of Kasemrad brand will be opened in next three years at Ramkamhang in 2018, Chiang-Khong in 2019, Sakaeo in 2020, Prachinburi in 2020 and Vientiance in 2020. BCH can increase their capacities of beds and exam rooms for IPD and OPD respectively. Moreover, the social security scheme patients increase from 2 new hospitals about 70 thousand people. Therefore, the overall performance of BCH will increase from the higher capacities of expansion new hospitals in strategic location.

1.1.4 Secured recurring income from social security scheme

Almost Kasemrad and Karunvej hospitals are participating in social security scheme. The centers of excellence were quantified as a Supra Contractor by Social Security Office that affect to continual growth. For year 2017, the number of registered person under the social security scheme increased on the average of 5.5 percent per annum that came from extra quota allowance during the year from social security office and the facilities improvement of the existing hospital. In addition, the announced SC quota of existing hospitals from Analyst Presentation in March 2018 is 140 thousand people and add up the new quota from 2 new hospitals about 70 thousand people. Therefore, BCH can secure its recurring income from social security scheme.

1.1.5 Macro environment favors to BCH

The ability to afford the healthcare is depend on their income due to the cost of private hospital is higher than government hospital. A hike in minimum wage in 2018 expect to boost consumer income in the short term. Thailand monthly income per household increased by 51% during 2007-17. This would support growing demand for private healthcare. In terms of total gross income, the middle youth and mid-lifers tend to focus their spending around the family, creating a favorable environment for marketers of household facilities, durables, education, and financial and healthcare services. The healthcare expenditure to GDP in Thailand is 3.8%. In 2018, it will increase by 3.6%. Health goods and medical services will be the second fastest-growing consumer category in 2018-2030. Moreover, the high-income countries tend to spend more on healthcare expenditure. For Thailand, total fertility rate has declined. In the meantime, life expectancy at birth has increased. Lastly, as older people become more dominant as both workers and consumers, population ageing will create new demands and present many opportunities.

1.2 Business Description

1.2.1 Business

Bangkok Chain Hospital Public Company Limited, BCH, was established in 1993 to provide medical treatment for patients as private hospitals in nursing business with paid-up capital of THB 2,494 millions. There are 14 chained hospitals in Bangkok vicinity, Chiang Rai, Saraburi, Nonthaburi, Pathumthani, Ayudhaya, Chachoengsao, Prachinburi, Sa Kaeo Province and Lao People's Democratic Republic with 3 chained hospitals not started commercial operation. In addition, BCH also provides consultation services, management services and the assets management services relevant to the hospital and property for rent. The group of hospitals consists of eleven hospital branches and two polyclinics to serve all types of customers. The company has mainly four centers of excellences which consist of Heart Surgery, Heart Center and Cardiac Cath Lab, Lasik and Eye Center, Imaging Center and Cancer Center to provide tertiary

care services to patients under BCH Group's hospitals and referred patients from over 40 allied hospitals that are the main contractor of Social Security Office and National Security Office with offered an exclusive rate. With the centers of excellences, the company can service treatment or surgery quickly that affect to improve efficiency of equipment utilization and raise assets turnover to the company as below figures showing the higher ROA and utilization rate of beds day.




Figure 1.2 Utilization rate of IPD: Beds day

Source: Annual report BCH 2017



Figure 1.3 ROA

Source: Annual report BCH 2017

1.2.2 Revenue

The main revenue of the company comes from several types of customer and regular income from the Social Security Scheme and Universal Coverage Scheme. There are **two types of patients** on regular basis, which consist of **cash patients and under government schemes** so the income from combined patient provides diversified sources of revenue. For **patients under the schemes**, Social Security Scheme and National Universal Coverage Office are responsible for the medical expenses incurred.

The company can create efficiency and productivity of their resources because of having various types of customers.

The nature of customers are Cash-base patients and Government schemes' customer group. Cash-base patients who select their preferred hospital by themselves are fully responsible for their own expenses. They also concentrate on quality of life with health conscious. Therefore, the company can provide value added health package such as the other alternative medicines and health check-up package. The second types of customers are Government schemes' customer group which consist of group of Civil servant medical benefit scheme, group of Social security scheme and group of Universal coverage scheme. The factor to increase the government official customer base is the location of each hospital which is in working community. Almost Kasemrad and Karunvej hospitals are participating in group of social security scheme. Moreover, the specialized center of the hospitals such as Heart center is qualified to be a referral center where patients from others hospitals to be acquired treatment up with tertiary care.

In 2017, the revenues structure of the company combined with about 62% from Cash-base patients, about 37% from Government schemes' customer group over the years and Universal Coverage patients 1%. Cash-base patients or walk in is the main revenue of the company that slightly decrease in year 2017. On the contrary, Government schemes' customer group lightly increase over the years because their centers of excellence were quantified as a Supra Contractor by Social Security Office that affect to continual growth. However, the company strives to maintain the portion of revenue as 70% for Cash-base patients and 30% for Government schemes' customer group because Cash-base patients who concentrate on quality of life with health conscious and fully responsibility for their own expenses generate higher profit for the company than other customers due to lower sensitive to price.




Figure 1.4 BCH's Revenue 2017 - Breakdown by type of patients

Table 1.3 BCH's Revenue 2017 - Breakdown by type of patients

Revenue Structure (MB)	201	7	201	.6	20:	15
Cash-Base Revenue (Walk-in)	4,476	62%	4,140	64%	3,740	65%
Social Security Scheme Revenue	2,717	37%	2,305	35%	1,963	34%
Universal Coverage Revenue	62	1%	66	1%	63	1%
Total Revenues	7,255	100%	6,511	100%	5,766	100%

Source: Annual report BCH 2017

1.2.3 Services and brands

Products and services of the hospitals depend on level of care that divided into three categories as primary care, secondary care and tertiary care. The primary care is generalized stop for symptoms and medical concerns which is typically responsible for coordinating patient's care among specialists and other levels of care. Secondary care simply means taken care of by more specific expertise. Specialists focus either on a specific system of the body or a specific disease or condition. Tertiary care requires highly specialized equipment and expertise which includes severe burn treatments and any other very complex treatments or procedures.

The Company have **three brands** of the hospital which categorized by their types of target customers and level of excellent cares. The first brand is **World Medical Hospital Group (WMC)**, which focus on high-end and international patients by providing tertiary care which required high specialized medical services. WMC also services to referral patients from hospital in the group and other alliance hospitals nationwide. The second brand is KH group which consists of **Kasemrad Hospital**

Group (KH) and Kasemrad International Hospital Group (KIH). KH group concentrates on middle-income patients and social security patients by providing primary, secondary and up to some level of tertiary care. In addition, KH consists of Kasemrad Medical Center (KHMC), Kasemrad Community Clinic (KCC) and Kasemrad Better Life (KH Better Life). KHMC have five centers as Heart Surgery Center, Imaging Center, Lasik and Eyes Center, Cardiac Cath Lab Center and Cancer Center to serve comprehensive medical services in the level of tertiary care. KCC services primary care to outpatients in Mae-Sai District and Chiangsan District, Chiangrai province. KH Better Life focus on healthy lifestyle and alternative medicine with various types of services such as Aesthetics (Skin Care and Non-Invasive), Dental & Aesthetic Dentistry and Wellness Center (Health Check-up). The last brand is Karunvej Hospital Group (KV) which has mainly customers as social security patients that provide primary and up to secondary care.



Figure 1.5 Revenue by brands in 2017

Table 1.4 Revenue by brands in 2017

Brands	Target customers	Level of Excellence	Revenue by Brands in 2017 (MB)	% Revenue by Brands in 2017
		Tertiary care which required high		
WMC	High-end / International patients	specialized medical services.	567	8%
	Middle to High income patients	Primary, secondary and up to		
KH & KIH	and Social security patients	some level of tertiary care	5,910	81%
KV	Mainly social security patients	Primary and up to secondary care	778	11%

Source: Annual report BCH 2017 and Analyst Presentation BCH 4Q2017

1.2.4 Management and Administration

The company operates under group policies therefore each hospital applies the same directions which are guided by top management. In addition, the knowledge sharing policies are exchanged between the hospitals such as administrative experiences. Moreover, the top management is an acting president of the Private Hospitals Association and has many important roles in a national healthcare administrative level so the business operations is well managed. The company can well adapt and resolve in line of the current economic situations from experiences of top management. The top management introduced the centers of excellences to the group that aim to reduce referral costs and once group of the hospitals so the company also gain advantage because those centers of excellence were quantified as a Supra Contractor by Social Security Office that affect to continual growth.

The key indicator to measure annualized rate of return is CAGR as the higher the better as below figures. The Compound Annual Growth Rate (CAGR) is very useful for investment analysis which are also referred to as the annualized rate of return or annual percent yield or effective annual rate. Over the past five years, the utilization rate of IPD cash patients and social security patients grew on average of 6.6 percent per annum. In 2017, the factors which helped surging the number of patients are upgrading the hospital standards to support the expansions of local communities and increasing number of specialized clinic center to help complication treatment. For the utilization rate of OPD, it raised on the average of 3.9 percent per annum on average over the past five years because of the support from social security office for their patients under the scheme to receive a health checkup service and expansion of the mobile medical services in several provinces in Thailand. In addition, the number of registered person under the social security scheme increased on the average of 5.5 percent per annum that came from extra quota allowance during the year from social security office and the facilities improvement of the existing hospital.




Figure 1.6 IPD-Utilization rate per year




Figure 1.7 OPD-Utilization rate per year




Figure 1.8 SS-CAGR Numbers of registered persons

Source: Annual report BCH 2017

1.2.5 Strategies

BCH group's hospital aim to build their brand to be a number one preferred hospital in patients' mind. So they focus on Brand strategy to create strong four brands as World Medical Hospital Group (WMC), Kasemrad Hospital Group (KH), Kasemrad International Hospital Group (KIH) and Karunvej Hospital Group (KV). Each brand serves different types of customers in order to capture all of market segments. The overview of BCH brand is only one brand who focus on social security patients to highend and international patient as low-medium-high group of customers. Generally, the company strives to manage their risk to be low by having about 70% of revenue from Cash-base patients and about 30% of revenue from Government schemes' customer group. The goals of the company can be achieved by developing a successful brand which combine their company's character that customers can identify. To create brand loyalty is hard to succeed that requires marketing communication and word of mouth strategy. For example, the company launched the marketing campaign to create brand awareness called "Happiness Observer" to enhance brand awareness. Moreover, the strategic location of the company is the key to build brand image. For instance, World Medical Hospital Group (WMC) located on Chaeng Watthana road which is affluent residential neighborhoods because WMC focus on high- end patients. WMC also concentrate on international patient so Chaeng Watthana road is not far from Don Mueang International Airport that provide convenience for international patients. Especially, ASEAN country who is their main customers such as Myanmar and Pakistan. However, Europe also is the major patients of this brand. Moreover, BCH launched two campaigns to raise brand awareness as "Best Job in Thailand" and "Kasemrad Super Run" that gain good responses by a lot of people in 2017.

In the future, the company plans to Re-branding of the existing hospitals. World Medical Hospital launched the marketing campaigns such as the perception about the ability to provide the best medical service with reasonable price to target local hieral patients and international patients. In addition, Hospitals' rebranding will be implemented for brand Karunvej.

The company also apply Expansion strategy to gain more market share. The company increase their new hospital in the strategic location which is the zone of target customers and far from their competitors. For example, Karunvej concentrate on the

patients under social security scheme so it was located at Navanakorn industrial estate, Sukhaphiban 3, Ayutthaya and Pathum Thani. So the workers will choose Karunvej because it provides convenience. The company continuously expand the new hospital in various strategic location to enhance new customers. Nowadays, the company gain the highest patients under social security scheme about 1 million persons. In addition, the company have to expand more hospital to increase its service coverage for cash patients, patients under social security scheme and patients around the borders. The local and international business expansion is their strategies in the future plan. The five more hospital branches both locally and internationally of Kasemrad brand will be opened in next three years at Ramkamhang in 2018, Chiang-Khong in 2019, Sakaeo in 2020, Prachinburi in 2020 and Vientiance in 2020.

For Customer strategy, the company strives to provide better service to its patients. Therefore, to enhance standard of the hospitals, it will manage to add medical specialties centers into the hospitals that located in the strategic locations such as Heart Center and Imaging Center in order to upgrade them to be the referral centers for patients from different region in Thailand. In addition, the company plan to renovate facilities in the hospital as well as improve operational process to be better efficiency. Training staff is important way to improve the skill of them that will help to enhance hospital's standard. When the company provides quality services that helps it to gain more new patients and keep existing patients as well as create its brand loyalty in the future.

1.2.6 Corporate Governance

The company's management and administrations are efficient, transparent and auditable so the shareholders, investors and other stakeholders are trust and confidence to the company. The company realizes that good corporate governance shall add a firm's value and contribute to sustainable growth of the company therefore the company has complied with the corporate governance guidelines in five sections which consist of Shareholders' right, Fair and equitable treatment to shareholders, Awareness in stakeholders, information disclosure and transparency and Directors' responsibility. To ensure company's good governance, BCH had been received certificate from Thailand's Private Sector Collective Action Coalition Against Corruption. Moreover, to reflect the commitment of BCH to operate its business in line with good corporate

governance, the company obtained "Good" rating in CGR report from Corporate Governance Report of Thai Listed Companies in 2017.

1.3 Macro-Economic Analysis

1.3.1 Private hospital in nutshell

The government has a policy to encourage public access to health service. All the Thai people are given right to access to government hospital at low cost. The private hospital gets benefit from government promotion by contribution through the social security program as one part of revenue. However, for Thais who does not have social security. The ability to afford the healthcare is depend on their income due to the cost of private hospital is higher than government hospital. A hike in minimum wage in 2018 expect to boost consumer income in the short term. Thailand monthly income per household increased by 51% during 2007-17. This would support growing demand for private healthcare.

In terms of total gross income, the largest concentration can be witnessed in the age segment 37-55 and a small concentration was found in the age group 17-27, reflecting the high proportion of the population belonging to these age. The middle youth and mid-lifers tend to focus their spending around the family, creating a favorable environment for marketers of household facilities, durables, education, and financial and healthcare services.




Figure 1.9 Monthly Income Per Household

1.3.2 Health expenditures is lower than other countries

The healthcare expenditure to GDP in Thailand is 3.8% (both the government spending and the private expenditures). The number showed that Thailand spend on this portion is below than the average (World 6.3%). In 2017, consumer expenditure per capita amounted to Bt125, 305 (US\$3,692). In 2018, it will increase by 3.6%. Communications will be the fastest- growing consumer category in 2018-2030 followed by health goods and medical services. (Source: Euromonitor)




Figure 1.10 % of Healthcare expenditure to GDP

1.3.3 Income and health expenditure

The high-income countries tend to spend more on healthcare expenditure. This link to the number of ICU beds per million populations. The higher spending on healthcare expenditure, the increase in number of beds and capacity of hospital.




Figure 1.11 Number of ICU beds per million population

1.3.4 Aging population

Population ageing, driven by rising life expectancy and falling fertility rates, is a powerful and transformative demographic force. The fertility rates of all developed countries have fallen below 2.1 children born per female, which is the rate needed for a developed nation to hold its population constant. For Thailand, total fertility rate has declined from over 6 births per woman in 1960s to below 2 in the mid of 1990. In the meantime, life expectancy at birth has increased from 55.2 to 69.9 years for men and 61.8 years to 74.9 years for women. The population in Thailand was 69.0 million in 2017, an increase of 6.1 million since 2000. Growth of population was relatively rapid in recent decades but is now decelerating. The slowdown means the country's pool of young workers will shrink in the medium term. Median age in 2017 was 38.8 years. It increases from 30.1 years in 2000. The gradually increase is a signal of an ageing process. Median age will reach 43.8 years in 2030. The number of elderly (those over

65 years) was 11.4% of the total in 2017 but the total will rise sharply by 2030. Result in this group represents 19.4% of total population.




Figure 1.12 Age pyramid in 2017 and 2030

Source: Euromonitor International from national statistic/UN

The lower middle class expect to remain the most prevalent in the country Overall, the large size of social classes in lower middle class and lower class in Thailand represents a vast market for necessities. Due to population ageing, the share of individuals aged more than 65 years old will rise significantly in lower middle class, creating demand for affordable healthcare products and services. Ageing also presents challenges such as a shrinking labor force, reduced savings leading to depressed investment and growth, and increasing government spending on healthcare and pensions. However, as older people become more active as both workers and consumers, population ageing will create new demands and present many opportunities.

1.4 Industry Analysis

There are over 1,000 hospitals in Thailand, of which over 470 are private facilities. Thailand have the largest private hospital in Asia, as well as Bumrungrad is the first Asian hospital to receive the ISO 9001 certification and JCI accreditation. Moreover, all of the JCI accredited hospital in Thailand are all private.

1.4.1 Asia healthcare medical hub

The strong support from government to promote Thailand 4.0 by putting healthcare as one of a priority sector. The government spends 14% of its total budget on the healthcare industry, which accounts for 4.6% of Thailand's GDP. This is considered to be the highest among ASEAN countries. The advantage of location which is place in a well-positioned to be the medical hub of the region. An excellent medical foundation that includes world-class medical facilities such as highly accredited doctors and using of sophisticate technology and equipment. The using of advance healthcare services at highly competitive prices, qualified healthcare specialists and various internationally accredited medical facilities. This provide competitive advantage for Thailand healthcare industry over ASEAN countries. Thai medical services are well known, resulting in a rapid growth in supporting industries such as pharmaceuticals, laboratory tests and clinical R&D. The ten year strategic plan start from 2016 proposes to turn Thailand into a medical hub in four major areas: wellness, medical services, academics and products.




Figure 1.13 Competitiveness of Thai Private Hospital vs. Other in ASEAN

1.4.2 Digital Innovation integrated in healthcare

Technology and innovation is crucial for sustained economic growth for the medical and healthcare sector. Data from the National Electronics and Computer Technology Centre (NECTEC) and the National Broadcasting and Telecommunications Commission (NBTC), indicate that ICT adoption is increasing. The country's

broadband subscribers in the latter quarter of 2014 reached more than 5 million, totaling nearly 27% broadband penetration/household. Mobile phone use has also reached 120% in the country in 2015. This bring internet come to people daily life in hand. It creates the opportunity for healthcare apps which will allows digital healthcare to become an integrated part of people lives. The benefits of healthcare apps are for patients, providers and doctors. It allows patient to find information on their health condition adapt to individual, make an appointment, pay their healthcare bills and so on. The provider can collect information from the apps to improve the management of hospital workflows, coordinate with vendors, reducing their cost of operation. The doctors can easily access to patients' information and communicate with their patients 24/7 as well as tracking record and set plan for reviving patients individually.

1.4.3 Health awareness

By 2030, Thai people will consist of 65+ years old about 19.4% of total population as mentioned above. Hence, the demand for healthcare service and medical treatment will upsurge and the business can grow much further. The internet penetration and the use of social media bring news quickly result in increase of health awareness. People put more serious on health condition and increase health conscious lifestyle. Therefore, there are concern start from the food, drink. The increase trend and encourage people to do exercise, reduce their smoking habit. All of these improve people's health awareness. There will be much more opportunities from this industry to support these demand

1.4.4 Medical tourism

Thailand is one of the top target for medical tourism, capable of medical personal, convenient infrastructure and facilities. It is largely driven by private hospitals. The number of medical tourists that come in Thailand has been steadily increasing since the early 2000's. This has resulted in the country taking its place on the top of the global medical tourism market. The main reasons that have enabled Thailand to dominate this growing market are: the low cost of medical treatment than their home country, the quality of treatment provided by private medical centers and the highly developed tourism industry from the rich culture and friendly personality to foreigners. Foreigner

patients come from many countries such as UAE, China and Cambodia. The service prefers to do in Thailand for example cosmetic and plastic surgeries, the operation cost a small amount compare to what patients in US and UK would pay back at home. The cardiac procedures, Thailand has many hospitals specialize in heart. They have their own cardiac surgery centers which can perform heart bypass, heart valve replacement and many at high quality standard and competitive price.



Figure 1.14 Trend of Medical tourist to Thailand

Tuble Tie Tilee and procedure comparison	Table 1.5	Price and	procedure	comparison
--	------------------	-----------	-----------	------------

Procedures (In USD)	USA	Singapore	Thailand	Malaysia	India
Heart Bypass	123,000	17,200	15,000	12,100	7,900
Heart Valve Replacement	170,000	16,900	17,200	13,500	9,500
Knee Replacement	35,000	16,000	14,000	7,700	6,600
Spinal Fusion	110,000	12,800	9,500	6,000	10,300
IVF Treatment	12,400	14,900	4,100	6,900	2,500

1.5 Competition Analysis

The briefly analysis currently performance of BCH's competitors consisted of BDMS, BH, RAM, CHG and THG. The main competitor to compare with BCH is Vibhavadi Medical Center Public Company Limited and its Subsidiaries, in short VIBHA. The analysis of financial performance in detail with the historical financial statement and forecasted financial statement in various dimensions. It is divided into size analysis, common size analysis, CAGR, and financial ratio.




Figure 1.15 Revenue 2017 - Breakdown by private hospitals

Source: Team calculate from data of Bloomberg and SET




Figure 1.16 Market Capital 2017 - Breakdown by private hospitals

Source: Team calculate from data of Bloomberg and SET

BDMS, Bangkok hospital was the top 5 private hospital operators in the world by market capitalization with company and its subsidiaries. BDMS has 45 network hospitals. The capacity of inpatients is about 8,000 beds. BDMS concentrate on High-end and international patient and intend to become Center of Excellence (CoE). The revenue of BDMS consist of 72% for Thai patients and 28% for international patients. BDMS reports the totals revenue of 72,772 MB which increase 6% from the previous year. The higher performance mainly came from strong patient referral system and synergies and benefits scale among hospitals within the group.

BH, Bumrungrad Hospital Public Company Limited, operates a premium private hospital business with capacity 5,500 outpatients and 580 beds per day in

Bangkok which is the leading healthcare providers in Thailand and Southeast Asian region. BH focus on High-end and international patient that is appropriate to compare with WMC of BCH group but the size of BH is higher than WMC. The BH's historical revenue contribution of international patients over the past five years is about 63% and the remainder for Thai patients. In addition, the average utilization rate of last three years was 70% for IPD and 54% for OPD. In 2017, BH reported total revenues of 18,527 MB which mainly comes from revenues from hospital operations as 18,279 MB. The revenue from hospital operations increases from previous year about 2.4% because of the increase in revenues from Thai and foreign patients by 2.3% and 3.1% respectively. Moreover, the cost of hospital presented 10,460 MB in 2017 which increase 0.5% from 2016. Administration expenses were 0.1% higher a bit than expenses in 2016. So this represents a favorable change to Net profit as an 8.8% improving year-over-year. Basic EPS for 2017 was 5.41 that 8.8% more than 4.98 in 2016.

RAM, Ramkhamhaeng hospital, operates a private hospital business with offering medical services that focus on middle-income patients and social security patients. The hospital provides capacity of 485 beds for inpatients and 2,500 persons for outpatients with average utilization rate of last three years as 50% for IPD and 60% for OPD. In 2017, RAM reported total revenue of 4,173 MB which increase 1.38% from previous year and Net profit presented 1,322.12 MB that was higher than last year about 17.36%. The higher performance mainly came from increasing of other income which combined of profit of investment in associate and dividend income.

CHG, Chularat Hospital Public Company Limited, operates a private hospital business which provide services to 2 main types of customers, General patients and social welfare patients. The total capacity are 705 beds for IPD and 6,000 cases for IPD. The revenue of hospital operations was reported as 3,876 MB which increased 6.57 % from last year. The company focus on middle-income patients and social security patients. The key factors which increased company's income were increasing general patients, higher average income by case, increasing number of people with social security account and medical service fee received from social security account. From aforementioned factors, the company maintained a steady profit. In 2017 the company had 565 MB which slightly increased from previous year about 2.48% and could

maintain profit rate higher than the industry average. The company could maintain good control on principal costs.

THG, Thonburi Healthcare group, operates a private hospital business by providing three major segment as Medical Services business, Healthcare Solution provider and other business that focus on middle-income to high-end patients and social security patients. The capacity to service are 5,580 outpatients daily and 435 beds for inpatients. In 2017, total revenue presented 6,611 MB which were higher than last year 6.1% and gross profit slightly increased 0.2%. So the net profit was reported 554 MB which was more than previous year 8.4%.

BCH as the fourth highest market capital and revenue has capacity for IPD of 2,178 beds and examination room for OPD of 414 rooms in 2017. BCH as the large hospital with more extended business network can gain advantage of economies of scale, a strong capital base and flexibility in marketing domestically and internationally. Due to their large size, BCH can absorb pressures arising from a changing business environment better than small and medium competitors. In addition, BCH still expand their hospital into strategic location which currently have 5 projects in pipeline. BCH captures all of market segments. The overview of BCH brand is only one brand who focus on social security patients to high-end and international patient as low-mediumhigh group of customers. Moreover, BCH strives to provide better service to its patients due to enhance standard of the hospitals, they manage to add medical specialties centers into the hospitals that located in the strategic locations. Currently, the company gain the highest patients under social security scheme about 1 million persons. Moreover, it will plan to open more hospital to gain more patients under scheme. BCH also gain advantage over their competitors because BCH Group's hospitals has referred patients from over 40 allied hospitals that are the main contractor of Social Security Office and National Security Office with offered an exclusive rate. With the centers of excellences, the company can service treatment or surgery quickly that affect to improve efficiency of equipment utilization and raise turnover to the company. So with the factors that mention before, BCH can well competitive in the market that reflected higher performance over the years and strong balance sheet which came from their good strategy.




Figure 1.17 Pricing comparison

When comparing the price, premium hospital bill is more expensive than private hospital by 250%. BH as the premium hospital has average hospital bill (IPD) per day is higher than average Malaysia hospital by 38% but lower than Singapore by 14% that is still competitive in the international market. WMC is the premium hospital like BH with quite similar service rate that focus on high-end to international patients. So BH can be representative for WMC in the market. While BCH as private hospital charged at lower price than average by 50% which is competitive price in the domestic and international market.



Figure 1.18 Five force analysis of BCH

The five force analysis of BCH shown that BCH had high sector competition because there are many private hospitals in the same areas especially in Bangkok. Although, the largest hospitals as BCH dominate high market shares. Moreover, expansion medical service as opening after-hours clinics, many private hospitals have set up specialized tertiary centers to serve full medical services and to provide more new services with attractive pricing and promotion to compete. High threat of substitute products and services, the patients can choose to seek treatment in public hospitals or clinics. However, the private hospitals can provide more complex treatments and better services which are required for many patients. Medium bargaining power of customers, most of patients focus on hospital facilities and special clinics rather than a well-known doctor. In addition, patients have a little sensitive in price due to necessary services. However, some patients can switch hospital choice at a low cost for a not serious case. The private hospitals may offer a wide variety of health insurance packages. Low bargaining power of suppliers, most of private hospitals have own companies to purchase drugs and source medical equipment. The pharmaceutical manufacturers are high competition especially for local manufacturers. Low threat of new entrants, the private hospitals require high investment for a 100 bed hospital typically costs more than 1,000 MB. Moreover, the suitable land sites are scare especially in high traffic provinces such as Bangkok, Chiang Mai and Pattaya. The available qualified and experienced doctors are also limit.

1.6 Financial Statement Analysis

Table 1.6 Profit / (Loss) - Compare with Peer

PL-Compare with Peer							
ВСН				Year E	nding Dec	. 31,	
Income Statement (MB)	CAGR	Common Size 2017	2017	2016	2015	2014	2013
Revenues from hospital operations	9%	100%	7,255	6,511	5,766	5,301	4,702
Cost of hospital operations	2%	67%	4,877	4,472	3,989	3,670	3,191
Gross profit	10%	33%	2,378	2,039	1,777	1,631	1,510
Other incomes	2%	1%	107	98	86	80	95
Distribution costs	29%	2%	120	87	64	74	34
Administrative expenses	8%	12%	840	748	791	647	566
EBIT	9%	21%	1,526	1,303	1,010	990	1,005
Finance costs	5%	2%	136	162	163	160	106
In ω me tax expense	9%	4%	271	208	174	159	178
NI	9%	15%	1,119	933	673	671	721
Gross profit rate			33%	31%	31%	31%	32%
Operating profit rate			20% 18% 16% 17%				19%
VIBHA				Year E	nding Dec	. 31,	
Income Statement (MB)	CAGR	Common Size 2017	2017	2016	2015	2014	2013
Revenues from hospital operations	6%	100%	5,983	5,602	5,242	4,750	4,371
Cost of hospital operations	6%	68%	4,040	3,734	3,472	3,246	2,955
Gross profit	7%	32%	1,943	1,867	1,770	1,504	1,415
Othe <mark>r in</mark> comes	15%	2%	110	86	72	77	54
Distribution costs	-100%	0%	-	-	13	12	13
Administrative expenses	7%	15%	871	860	733	668	617
EBIT	8%	24%	1,414	1,212	1,260	1,042	969
Finance costs	14%	3%	153	122	108	99	81
Inαme tax expense	4%	3%	196	225	211	170	161
NI	8%	18%	1,065	866	941	773	727
Gross profit rate			32%	33%	34%	32%	32%
Operating profit rate			18%	18%	20%	17%	18%

In 2017, the revenue from hospital operations of BCH increased from previous year by 11 percent from 6,511 MB to 7,255 MB. And net profit raised from 933 MB to 1,119 MB about 20% because of budget allocation to the hospitals in the scheme by the Social Security Office (SSO) since July 1, 2017 an increase in number of SSO insurers in its chain hospital and higher general walk-in patients that create an improved performance. When comparing income statement with the key competitor as VIBHA, revenues from hospital operations of BCH is higher than VIBHA because of BCH is larger size than VIBHA. So in 2017 the revenue of BCH presents 7,255 MB increasing 9% over 5 years and VIBHA presents 5,983 MB increasing 6% over 5 years.




Figure 1.19 Revenue of hospital operations - Compare with Peer

BCH's cost of hospital operations is 4,877 MB which is also higher than VIBHA as 4,040 MB. Cost of BCH slightly increase about 2% over the years on the contrary cost of VIBHA raise about 6% over the years. The gross profit margin of two companies is reported 33% for BCH and 32% for VIBHA that is quite similar. Moreover, BCH can maintain gross profit margin to increase over the years but gross profit margin of VIBHA slightly drops over the years. CAGR of gross profit margin show 10% for BCH and 7% for VIBHA. Therefore, BCH can generate higher profit over the year and control their cost efficiently.




Figure 1.20 Cost of hospital operations - Compare with Peer

In term of common size, performance of BCH and VIBHA depend on Sales and Cost to generate net profit. Distribution costs and administrative expense of BCH also are higher than VIBHA. VIBHA can maintain their expenses very well due to showing lower amounts over the years. However, EBIT of BCH is more than VIBHA that comes from higher sales of BCH. Finance cost of BCH is 136 MB with 5% CAGR and VIBHA is 153 MB with 14% CAGR. Interest bearing debt of BCH is 5,345 MB which is higher than VIBHA as 3,523 MB that show the ability of BCH to maintain lower cost of debt than their competitor. For the tax expenses of BCH, it is higher than VIBHA because of generating profit more than VIBHA. The bottom line of two

companies as Net income present 1,119 MB for BCH and 1,065 MB for VIBHA in 2017 so the performance of BCH is better than VIBHA due to their solid operation.




Figure 1.21 Net income - Compare with Peer



Table 1.7 BCH's Statement of financial position

Historical Financial Stateme	ent 10	r BCH					
	CAGR	Common		Year I	Ending Dec	c. 31,	
Balance Sheet (MB)	CAGK	Size 2017	2017	2016	2015	2014	2013
Assets							
Cash and cash equivalents	-13%	4%	486	513	675	466	98
Current investments	37%	12%	1,580	168	131	143	32
Trade accounts receivable	7%	8%	1,054	997	1,077	1,099	759
Other receivables	-1%	0%	37	48	48	34	39
Inventories	5%	2%	204	195	189	178	164
Other Current Assets	-8%	0%	3	17	17	13	4
Total Current Assets	8%	27%	3,364	1,937	2,137	1,933	2,27
Doctricted deposits	-54%	0%	1	1	19	39	38
Restricted deposits Investment in associate	-54% 0%	0%	7	7	7	39	38
						_	
Other long-term investments	79%	0%	43	38	37	48	2
Long-term loan to related party	0%	0%		3	6	- 674	-
Investment properties	0%	8%	973	669	671	674	7.400
Property, Plant, and equipment, Net	1%	61%	7,744	7,371	7,188	6,884	7,403
Goodwill	10%	3%	329	329	329	202	202
Intangible assets Deferred tax assets	17%		142	142	121	87	66
	4%	0%	28	27	36	32	22
Other non-current assets	12%	0%	43	46	46	91	24
Total Non-Current Assets	4%	73%	9,310	8,633	8,461	8,058	7,757
Total Assets	5%	100%	12,674	10,569	10,598	9,992	10,030
Liabilities and Shareholders' Equity							
Short-term borrowings from financial	2501	4.07	450	0.0	4 400		
institutions	-25%	1%	150	80	1,138	694	620
Trade accounts payable	3%	4%	458	413	355	338	399
Payables for hospital equipment and medical instruments	-5%	1%	97	44	54	61	124
Current portion of long-term loans from	-5%	1%	97	44	54	- 61	124
financial institutions	-100%	0%	_	_	14	13	16
Current portion of debentures	0%	8%	1,000	1,500	800		_
Current portion of finance lease liabilities	-100%	0%	-	16	76	82	89
Current income tax payable	13%	1%	126	69	66	65	69
Accrued expenses	2%	3%	375	387	395	365	347
Deferred income	-19%		19	55	58	54	55
Other current liabilities	-12%	0%	51	59	86	133	96
Total Current Liabilities	5%	18%	2,276	2,621	3,042	1,803	1,815
	5 70	1070	2/2/0	2,021	0,012	2,000	1,010
Long-term borrowings from financial							
institutions	108%	15%	1,847	-	10	24	47
Debentures	-5%	20%	2,498	2,498	2,500	3,300	3,300
Finance lease liabilities	-100%	0%	-	-	16	94	170
Non-current provision for employee							
benefit	8%	1%	117	100	95	83	8:
Other non-current liabilities	-19%		24	13	13	20	72
Total Non-Current Liabilities	4%	35%	4,486	2,611	2,634	3,522	3,669
Total Liabilities	4%	53%	6,762	5,233	5,676	5,325	5,485
Issued and paid-up share capital	0%	20%	2,494	2,494	2,494	2,494	2,49
Premium on share capital	0%		645	645	645	645	64.
Retained Earnings	0 70	0%	-	-	-	-	-
Appropriated – legal reserve	2%		249	249	249	249	22
Unappropriated	25%		1,837	1,387	985	758	59
Other components of equity	0%		(31)	(14)	(15)	(8)	29
Equity attributable to the company				4,761			2.06
	6%		5,195	-	4,359	4,137	3,96
Non-controlling interests	4%		717	576	563	530	58
Total equity Total Liabilities and Shareholders'	5%	47%	5,912	5,337	4,922	4,667	4,54
Equity	5%	100%	12,674	10,569	10,598	9,992	10,030

Table 1.8 VIBHA's Statement of financial position

Assets Cash and cash equivalents Current investments Trade accounts receivable Short-term loans to related parties Inventories	11% -10% -9% -9% -3% -100% 21% -3% -15% -15% -6% -10% -4% -13% -13% -5% -12%	0% 3% 2% 1% 0% 0% 9% 0% 23% 15% 6% 0% 2% 39% 5% 0% 0%	2017 433 1 520 294 155 - 32 1,433 43 3,579 2,358 955 30 - 233 6,043	2016 235 7 504 123 140 16 23 1,048 46 3,840 2,180 965 30 -236	323 1 460 313 128 - 35 1,261 35 2,586 1,284 861 6	249 1 495 343 136 47 17 1,288 41 2,478 1,021 740	2013 255 1 345 463 131 47 12 1,255 30 1,789 834 480
Cash and cash equivalents Current investments Trade accounts receivable Short-term loans to related parties Inventories Accrued dividend Other Current Assets Total Current Assets Fixed deposits pledged as collateral Available-for-sale investments Investments in associates Other long-term investments Long-term loans to related parties Long-term loans to other persons Investment property Property, plant and equipment Goodwill Intangible asset Deferred tax assets Advance payment for assets Other non-current assets Total Assets Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts	-10% 9% -9% 3% -100% 21% 3% 8% 15% 23% 6% 10% 6% 10% -4% -13% -13% -5%	3% 0% 3% 2% 1% 0% 0% 9% 23% 15% 6% 0% 2% 39% 5% 0%	433 1 520 294 155 - 32 1,433 43 3,579 2,358 955 30 - 233 6,043	235 7 504 123 140 16 23 1,048 46 3,840 2,180 965 30	323 1 460 313 128 - 35 1,261 35 2,586 1,284 861	249 1 495 343 136 47 17 1,288 41 2,478 1,021 740	255 1 345 463 131 47 12 1,255 30 1,789 834
Cash and cash equivalents Current investments Trade accounts receivable Short-term loans to related parties Inventories Accrued dividend Other Current Assets Total Current Assets Fixed deposits pledged as collateral Available-for-sale investments Investments in associates Other long-term investments Long-term loans to related parties Long-term loans to other persons Investment property Property, plant and equipment Goodwill Intangible asset Deferred tax assets Advance payment for assets Other non-current assets Total Non-Current Assets Total Assets Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Liabilities under finance ease contracts	-10% 9% -9% 3% -100% 21% 3% 8% 15% 23% 6% 10% 6% 10% -4% -13% -13% -5%	0% 3% 2% 1% 0% 0% 9% 0% 23% 15% 6% 0% 2% 39% 5% 0% 0%	1 520 294 155 - 32 1,433 43 3,579 2,358 955 30 - 233 6,043	7 504 123 140 16 23 1,048 46 3,840 2,180 965 30	1 460 313 128 - 35 1,261 35 2,586 1,284 861	1 495 343 136 47 17 1,288 41 2,478 1,021 740	1 345 463 131 47 12 1,255 30 1,789 834
Current investments Trade accounts receivable Short-term loans to related parties Inventories Accrued dividend Other Current Assets Fixed deposits pledged as collateral Available-for-sale investments Investments in associates Other long-term investments Long-term loans to related parties Long-term loans to other persons Investment property Property, plant and equipment Goodwill Intangible asset Deferred tax assets Advance payment for assets Other non-current assets Total Non-Current Assets Total Assets Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts	-10% 9% -9% 3% -100% 21% 3% 8% 15% 23% 6% 10% 6% 10% -4% -13% -13% -5%	0% 3% 2% 1% 0% 0% 9% 0% 23% 15% 6% 0% 2% 39% 5% 0% 0%	1 520 294 155 - 32 1,433 43 3,579 2,358 955 30 - 233 6,043	7 504 123 140 16 23 1,048 46 3,840 2,180 965 30	1 460 313 128 - 35 1,261 35 2,586 1,284 861	1 495 343 136 47 17 1,288 41 2,478 1,021 740	1 345 463 131 47 12 1,255 30 1,789 834
Trade accounts receivable Short-term loans to related parties Inventories Accrued dividend Other Current Assets Total Current Assets Fixed deposits pledged as collateral Available-for-sale investments Investments in associates Other long-term investments Long-term loans to related parties Long-term loans to other persons Investment property Property, plant and equipment Goodwill Intangible asset Deferred tax assets Advance payment for assets Other non-current assets Total Non-Current Assets Total Assets Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts	9% -9% 3% -100% 21% 3% 8% 15% 23% 0% 6% 10% 0% -4% -13% -5%	3% 2% 1% 0% 0% 9% 0% 23% 15% 6% 0% 0% 2% 39% 5% 0%	520 294 155 - 32 1,433 43 3,579 2,358 955 30 - 233 6,043	504 123 140 16 23 1,048 46 3,840 2,180 965 30	460 313 128 - 35 1,261 35 2,586 1,284 861	495 343 136 47 17 1,288 41 2,478 1,021 740	345 463 131 47 12 1,255 30 1,789 834
Short-term loans to related parties Inventories Accrued dividend Other Current Assets Total Current Assets Fixed deposits pledged as collateral Available-for-sale investments Investments in associates Other long-term investments Long-term loans to related parties Long-term loans to other persons Investment property Property, plant and equipment Goodwill Intangible asset Deferred tax assets Advance payment for assets Other non-current assets Total Assets Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts	-9% 3% -100% 21% 3% 8% 15% 23% 15% 6% 6% 10% -4% -13% -13% -5%	2% 1% 0% 0% 9% 0% 23% 15% 6% 0% 0% 2% 39% 5% 0%	294 155 - 32 1,433 43 3,579 2,358 955 30 - 233 6,043	123 140 16 23 1,048 46 3,840 2,180 965 30	313 128 - 35 1,261 35 2,586 1,284 861	343 136 47 17 1,288 41 2,478 1,021 740	463 131 47 12 1,255 30 1,789 834
Inventories Accrued dividend Other Current Assets Total Current Assets Fixed deposits pledged as collateral Available-for-sale investments Investments in associates Other long-term investments Long-term loans to related parties Long-term loans to other persons Investment property Property, plant and equipment Goodwill Intangible asset Deferred tax assets Advance payment for assets Other non-current assets Total Non-Current Assets Total Assets Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts	3% -100% 21% 3% 8% 15% 23% 15% 39% 6% 6% 10% -4% -13% -13% -5%	1% 0% 0% 9% 0% 23% 15% 6% 0% 2% 39% 5% 0%	155 - 32 1,433 43 3,579 2,358 955 30 - 233 6,043	140 16 23 1,048 46 3,840 2,180 965 30	128 - 35 1,261 35 2,586 1,284 861	136 47 17 1,288 41 2,478 1,021 740	131 47 12 1,255 30 1,789 834
Accrued dividend Other Current Assets Total Current Assets Fixed deposits pledged as collateral Available-for-sale investments Investments in associates Other long-term investments Long-term loans to related parties Long-term loans to other persons Investment property Property, plant and equipment Goodwill Intangible asset Deferred tax assets Advance payment for assets Other non-current assets Total Non-Current Assets Total Assets Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts	-100% 21% 3% 8% 15% 23% 15% 39% 6% 6% -4% -13% -13% -5%	0% 0% 9% 0% 23% 15% 6% 0% 2% 39% 5% 0%	- 32 1,433 43 3,579 2,358 955 30 - 233 6,043	16 23 1,048 46 3,840 2,180 965 30	35 1,261 35 2,586 1,284 861	47 17 1,288 41 2,478 1,021 740	47 12 1,255 30 1,789 834
Other Current Assets Total Current Assets Fixed deposits pledged as collateral Available-for-sale investments Investments in associates Other long-term investments Long-term loans to related parties Long-term loans to other persons Investment property Property, plant and equipment Goodwill Intangible asset Deferred tax assets Advance payment for assets Other non-current assets Total Non-Current Assets Total Assets Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts	21% 3% 8% 15% 23% 39% 6% 6% 10% -4% -13% -13%	0% 9% 0% 23% 15% 6% 0% 2% 39% 5% 0%	32 1,433 43 3,579 2,358 955 30 - 233 6,043	23 1,048 46 3,840 2,180 965 30	1,261 35 2,586 1,284 861	17 1,288 41 2,478 1,021 740	12 1,255 30 1,789 834
Total Current Assets Fixed deposits pledged as collateral Available-for-sale investments Investments in associates Other long-term investments Long-term loans to related parties Long-term loans to other persons Investment property Property, plant and equipment Goodwill Intangible asset Deferred tax assets Advance payment for assets Other non-current assets Total Non-Current Assets Total Assets Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts	3% 8% 15% 23% 15% 39% 6% 10% 6% -4% -13% -13%	9% 0% 23% 15% 6% 0% 2% 39% 5% 0%	1,433 43 3,579 2,358 955 30 - 233 6,043	1,048 46 3,840 2,180 965 30	1,261 35 2,586 1,284 861	1,288 41 2,478 1,021 740	1,255 30 1,789 834
Fixed deposits pledged as collateral Available-for-sale investments Investments in associates Other long-term investments Long-term loans to related parties Long-term loans to other persons Investment property Property, plant and equipment Goodwill Intangible asset Deferred tax assets Advance payment for assets Other non-current assets Total Non-Current Assets Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts	8% 15% 23% 15% 39% 6% 10% 6% -13% -13%	0% 23% 15% 6% 0% 0% 2% 39% 5% 0%	43 3,579 2,358 955 30 - 233 6,043	46 3,840 2,180 965 30	35 2,586 1,284 861	41 2,478 1,021 740	30 1,789 834
Available-for-sale investments Investments in associates Other long-term investments Long-term loans to related parties Long-term loans to other persons Investment property Property, plant and equipment Goodwill Intangible asset Deferred tax assets Advance payment for assets Other non-current assets Total Non-Current Assets Total Assets Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts	15% 23% 15% 39% 0% 6% 10% -4% -13% -5%	23% 15% 6% 0% 0% 2% 39% 5% 0%	3,579 2,358 955 30 - 233 6,043	3,840 2,180 965 30	2,586 1,284 861	2,478 1,021 740	1,789 834
Available-for-sale investments Investments in associates Other long-term investments Long-term loans to related parties Long-term loans to other persons Investment property Property, plant and equipment Goodwill Intangible asset Deferred tax assets Advance payment for assets Other non-current assets Total Non-Current Assets Total Assets Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts	23% 15% 39% 0% 6% 10% -4% -13% -13%	15% 6% 0% 0% 2% 39% 5% 0%	2,358 955 30 - 233 6,043	2,180 965 30	1,284 861	1,021 740	834
Other long-term investments Long-term loans to related parties Long-term loans to other persons Investment property Property, plant and equipment Goodwill Intangible asset Deferred tax assets Advance payment for assets Other non-current assets Total Non-Current Assets Total Assets Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts	15% 39% 0% 6% 10% 0% -4% -13% -13%	6% 0% 0% 2% 39% 5% 0%	2,358 955 30 - 233 6,043	2,180 965 30	1,284 861	1,021 740	
Long-term loans to related parties Long-term loans to other persons Investment property Property, plant and equipment Goodwill Intangible asset Deferred tax assets Advance payment for assets Other non-current assets Total Non-Current Assets Total Assets Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts	39% 0% 6% 10% 0% -4% -13% -13%	6% 0% 0% 2% 39% 5% 0%	955 30 - 233 6,043	965 30 -	861	740	
Long-term loans to related parties Long-term loans to other persons Investment property Property, plant and equipment Goodwill Intangible asset Deferred tax assets Advance payment for assets Other non-current assets Total Non-Current Assets Total Assets Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts	0% 6% 10% 0% -4% -13% -13%	0% 2% 39% 5% 0%	233 6,043	-	6		
Long-term loans to other persons Investment property Property, plant and equipment Goodwill Intangible asset Deferred tax assets Advance payment for assets Other non-current assets Total Non-Current Assets Total Assets Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts	0% 6% 10% 0% -4% -13% -13%	0% 2% 39% 5% 0%	233 6,043	-	_	6	6
Investment property Property, plant and equipment Goodwill Intangible asset Deferred tax assets Advance payment for assets Other non-current assets Total Non-Current Assets Total Assets Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts	10% 0% -4% -13% -13% -5%	2% 39% 5% 0% 0%	6,043	236	_		
Property, plant and equipment Goodwill Intangible asset Deferred tax assets Advance payment for assets Other non-current assets Total Non-Current Assets Total Assets Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts	10% 0% -4% -13% -13% -5%	39% 5% 0% 0%	6,043		172	174	175
Goodwill Intangible asset Deferred tax assets Advance payment for assets Other non-current assets Total Non-Current Assets Total Assets Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts	0% -4% -13% -13% -5%	5% 0% 0%		5,377	4,405	3,969	3,748
Intangible asset Deferred tax assets Advance payment for assets Other non-current assets Total Non-Current Assets Total Assets Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts	-4% -13% -13% -5%	0% 0%	723	723	723	723	723
Deferred tax assets Advance payment for assets Other non-current assets Total Non-Current Assets Total Assets Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts	-13% -13% -5%	0%	10	12	15	13	13
Advance payment for assets Other non-current assets Total Non-Current Assets Total Assets Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts	-13% -5%		23	20	20	21	45
Other non-current assets Total Non-Current Assets Total Assets Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts	-5%	0%	10	5	13	73	20
Total Non-Current Assets Total Assets Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts			6	6	5	12	8
Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts			14,013	13,440	10,124	9,271	7,871
Liabilities and Shareholders' Equity Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts							
Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts	11%	100%	15,446	14,487	11,385	10,560	9,127
Bank overdarfts and short-term loans Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts							
Trade payables Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts	18%	7%	1,032	1,228	1,022	1,123	450
Current portion: Long-term loan from financial institutions Current portion: Liabilities under finance ease contracts	6%	2%	309	287	270	258	233
financial institutions Current portion: Liabilities under finance ease contracts		270	505	20,	2,0	200	
ease contracts	18%	5%	722	504	518	372	312
					_		
Short-term loans from related parties	16%	0%	10	7	4	3	5
Short-term loans norm related parties	15%	5%	814	602	363	420	406
Short-term loan from other persons	-4%	1%	207	212	275	269	252
Payable from acquisition of assets	-2%	0%	36	63	36	22	40
Share subscription payable	0%	0%	-	- / -		5	
Accrued doctor fee	3%	1%	170	152	151	144	146
Accrued expenses	7%	0%	71	56	70	57	50
Accrued dividends	-8%	0%	16	15	12	11	24
Income tax payable	2%	1%	100	88	100	81	90
Advance received from social security							
office	0%	0%	-	29	-	40	-
Other current liabilities	-4%	0%	48	47	43	43	59
Total Current Liabilities	11%	23%	3,534	3,291	2,863	2,848	2,068
Long-term loan from financial institutions	16%	11%	1,685	1,017	791	612	798
Liabilities under finance lease agreements	6%	0%	14	15	13	14	10
Liabilities under operating lease	F04	0.51					
agreements	5%		71	68	64	60	56
Deferred tax liabilities	7%		626	730	517	504	450
Employee benefit obligations	7%		134	116	113	98	94
Other non-current liabilities	24%		14	21	7	10	5
Total Non-Current Liabilities	12%	16%	2,545	1,967	1,505	1,299	1,413
Total Liabilities	12%	39%	6,079	5,258	4,369	4,147	3,481
			,			_	
Issued and paid-up share capital	1%		1,320	1,316	1,261	1,258	1,258
Premium on share capital	6%		2,377	2,346	1,846	1,818	1,818
Retained Earnings	0%						
Appropriated – legal reserve	9%		132	132	131	108	88
Unappropriated	25%		1,953	1,542	1,256	917	649
Other components of equity	21%		1,232	1,464	798	756	471
Equity attributable to the company	10%		7,013	6,800	5,292	4,856	4,284
Non-controlling interests	12%		2,354	2,430	1,724	1,556	1,362
Total equity	11%	61%	9,367	9,229	7,016	6,413	5,646
Total Liabilities and Shareholders' Equity	11%	100%	15,446	14,487	11,385		9,127

In view of financial position, BCH has smaller asset size with 12,674 MB in 2017 being classified into 3,364 MB current assets or 27% of total assets and 9,310 MB non-current assets or 73% of total assets. VIBHA has 15,446 MB being classified into 1,433 MB current assets or 9% of total assets and 14,013 MB or 91% of total assets. BCH has higher current assets so it is better than VIBHA because of higher liquidity. In term of investment, BCH mostly invest in current investment but VIBHA invest in long term investment. BCH is better than VIBHA because of high liquidity although BCH generated a bit lower interest income than VIBHA about 50 MB in 2017. In addition trade account receivable of BCH are quite high as 1,054 MB or 8% of total assets that mainly comes from Social Security Office and National Health Security Office with 78% less than 3 months. In 2017, BCH already has submitted the letter to Social Security Office which was during the process to follow up the collectability of the remaining that certain subsidiaries had partial receipt. The majority portion of non-current assets of BCH are Property Plant and equipment about 7,744 MB or 61% of total assets because it is normal hospital operation to initially generate assets to serve their customers. The higher fixed assets create the higher sales to the hospital. VIBHA has lower fixed assets that are reported of 6,043 MB or 39% of total assets. Besides, PPE of VIBHA increase about 10% over the years, BCH has constant PPE over the years as CAGR only 1% that show currently VIBHA highly invest in fixed assets. For BCH, they had large investment in WMC in 2013. However, BCH will plan to invest for 5 projects in 2018-2020 so their PPE will increase in the following years. AS the higher PPE of two companies, it reflects that BCH and VIBHA apply expansion strategy. In term of liabilities, BCH has larger size than VIBHA. BCH reported 6,762 MB or 53% of total assets and VIBHA reported 6,079 MB or 39% of total assets in 2017. BCH had high liabilities in 2017 because they would invest in 5 projects in next years but they have low amount of short term debt because of sufficient cash in operation. For VIBHA, they had high Bank OD for using in operation and high long term debt for investing in new projects. So BCH is better capital management than VIBHA because BCH has lower default risk due to higher portion of an extended payback period of more than one year with lower interest expenses when comparing with VIBHA.

Table 1.9 Summary of Cash flow - Compare with Peer

Compare with Peer					
BCH		Year E	nding Dec.	31,	
Statements of Cash Flows (Million Baht)	2017	2016	2015	2014	2013
Cash Flows from Operations	1,814	1,701	1,338	823	1,394
Cash Flows from Investing	(2,483)	(729)	(857)	(605)	(2,258)
Cash Flows from Financing	642	(1,134)	(272)	(736)	1,255
Net Change in Cash	(27)	(163)	209	(519)	391
Cash and cash equivalents at 1 January	513	675	466	985	594
Cash and cash equivalents at 31 December	486	513	675	466	985
•					
VIBHA		Year E	nding Dec.	31,	
Statements of Cash Flows (Million Baht)	2017	2016	2015	2014	2013
Cash Flows from Operations	1,376	1,250	1,304	950	979
Cash Flows from Investing	(1,407)	(1,908)	(874)	(1,047)	(1,156)
Cash Flows from Financing	228	570	(355)	91	245
Net Change in Cash	197	(88)	74	(7)	69
Cash and cash equivalents at 1 January	235	323	249	255	187
Cash and cash equivalents at 31 December	433	235	323	249	255

When comparing the statement of cash flow, Cash flow from operations of BCH presented as 1,814 MB in 2017 which was higher than VIBHA as 1,376 MB that mainly comes from high net profit. BCH and VIBHA have positive CFO over the year that shows the ability of the companies to generate cash from operation to support other activities. For BCH, the mainly increasing comes from the net profit about 62% of CFO in 2017 which generate cash to the company from 2013 to 2017. In addition, the second largest part of CFO is depreciation and amortization about 30% of CFO that is quite constant over the year aligned with PPE which is quite constantly. For VIBHA, the mainly increasing comes from the net profit about 77% of CFO which generate cash to the company from 2013 to 2017. In addition, the second largest part of CFO is depreciation and amortization about 28% of CFO that is higher over the year aligned with PPE which increase from their projects.

BCH and VIBHA have negative CFI is a good sign that the company more invests in building and equipment for their new hospital projects to support increasing of sales. Besides, after paying debt and dividend they have cash to invest in temporary investment to gain interest income. However, BCH has higher amount of CFI due to larger size.

BCH and VIBHA have positive CFF because they increase long-term loans to invest in their projects and decrease from repayment loans and paying the dividend

to shareholders and repay loans from financial institutions due to having cash from operation, CFO.

In conclusion, BCH has net change in cash quite low with negative sign in 2017 because they bring almost cash from operation to use in investing. VIBHA has net change in cash quite high in 2017 due to lower in investing. However, BCH has higher cash than VIBHA that is sufficient for their operation so BCH doesn't need to borrow more in short term loan. VIBHA has high amount of Bank overdrafts and short-term loans because they don't have enough cash for operation. Therefore, BCH can better manage cash than VIBHA.

1.6.1 Trend Analysis

Revenue from hospital operation of BCH increases over the year as well as cost of them. The increasing of revenue is higher than the increasing of cost so the net profit raise over the years especially in 2017 about 18%. Therefore, BCH always has good performance.




Figure 1.22 Profit and Loss Trend

In term of financial position of BCH, in assets side the major items are cash and cash equivalent and PPE as 16% and 61% respectively. Cash and cash equivalent increase over the years especially in 2017 which increase almost double of the base year because BCH plan to pay for their new projects. For PPE, it also increases about 56%

of the base years which mainly come from gradually receive assets from their new projects. In liability side, the main items are interest bearing debt which about three times of base year because BCH borrows for its new projects. Moreover for equity side, it mainly comes from unappropriated retained earning which increase over the years from its good performance.




Figure 1.23 Financial position Trend

1.6.2 Financial Ratio: Return

Table 1.10 BCH's financial ratio – Return

Financial Indicators for BCH

	2017	2016	2015	2014	2013
ROA	10.80%	10.35%	8.12%	8.30%	9.65%
Profit Margin (PM)	16.82%	16.01%	14.02%	14.94%	17.10%
Tax Change (TC)	1.00	1.00	1.00	1.00	1.00
Tax Management (TM)	1.03	1.05	1.03	1.05	1.03
Total Asset TurnOver (TATO)	0.62	0.62	0.56	0.53	0.55

	2017	2016	2015	2014	2013
ROE	22.31%	21.35%	17.44%	18.03%	19.22%
ROA	10.80%	10.35%	8.12%	8.30%	9.65%
Capital Structure Leverage (CSL)	2.07	2.06	2.15	2.17	1.99

Turnover Ratios	mmon e 2017	2017	2016	2015	2014	2013
Total Asset TurnOver (TATO)	100%	0.62	0.62	0.56	0.53	0.55
Accounts Receivable TurnOver (ARTO)	8%	7.08	6.28	5.30	5.71	6.02
Inventory TurnOver (ITO)	2%	24.42	23.28	21.75	21.50	20.95
Fixed Assets TurnOver (FATO)	61%	0.96	0.89	0.82	0.74	0.76
Accounts Payable TurnOver (APTO)	4%	11.22	11.66	11.54	10.00	9.51

Table 1.11 VIBHA's financial ratio – Return

Financial Indicators for VIBHA

	2017	2016	2015	2014	2013
ROA	8.14%	7.63%	9.56%	8.86%	9.61%
Profit margin (PM)	18.91%	17.31%	19.23%	17.55%	17.73%
Tax Change (TC)	1.00	1.00	1.00	1.00	1.00
Tax Management (TM)	1.08	1.02	1.04	1.05	1.04
Total Asseet TurnOver (TATO)	0.40	0.43	0.48	0.48	0.52

	2017	2016	2015	2014	2013
ROE	13.10%	12.16%	15.62%	14.46%	15.54%
ROA	8.14%	7.63%	9.56%	8.86%	9.61%
Capital Structure Leverage (CSL)	1.61	1.59	1.63	1.63	1.62

Turnover Ratios	Common Size	2017	2016	2015	2014	2013
Total Asset TumOver (TATO)	100%	0.40	0.43	0.48	0.48	0.52
Accounts Receivable TurnOver (ARTO	3%	11.69	11.63	10.98	11.31	13.31
Inventory TurnOver (ITO)	1%	27.39	27.84	26.29	24.28	24.13
Fixed Assets TurnOver (FATO)	39%	1.05	1.15	1.25	1.23	1.19
Accounts Payable TurnOver (APTO)	2%	13.61	13.45	13.12	13.24	12.61

In term of ROA, as if BCH has no debt and still pay taxes at the effective tax rate, out of 100 Baht of total assets, ROA would generate net income of 10.80 Baht which is higher than VIBHA as 8.14% ROA. The reasons show that BCH has higher total asset turnover (TATO) as 0.62 than VIBHA as 0.40 because BCH generate higher revenues with lower total assets. BCH has better operating performance without the effect from its capital structure.

By comparing ROE, BCH's ROE is 22.31%, meaning that out of 100 Baht of their equity investment, shareholders would get a return back in form of net income of 22.31 Baht which also greater than VIBHA. The factors of BCH that generate higher ROE are higher ROA that means BCH can generate higher return from their assets when compare with VIBHA. The other turnover ratios that impact to financial position of two companies are fixed assets turnover (FATO) with high common size. FATO of BCH as 0.96 is a bit lower than VIBHA as 1.05 because BCH has greater PPE than VIBHA.

1.6.3 Financial Ratio: Risk

Table 1.12 BCH's financial ratio - Risk Financial Indicators for BCH

Liquidity risk	2017	2016	2015	2014	2013
Current Ratio (CR)	1.48	0.74	0.70	1.07	1.25
Quick Ratio (QR)	1.39	0.66	0.63	0.97	1.16
Receivable Collection Period (RCP)	52	58	69	64	61
Inventory Conversion Period (ICP)	15	16	17	17	17
Payables Deferral Period (PDP)	33	31	32	37	38
Cash Conversion Cycle (CCC)	34	42	54	44	40

Solvency risk	2017	2016	2015	2014	2013
Debt -to-Equity ratio (DE)	92.9%	76.7%	92.5%	90.1%	93.3%
Debt-to-Total Assets ratio (DTA)	43.4%	38.7%	43.0%	42.1%	42.3%
Interest coverage ration (ICR)	11.2	8.0	6.2	6.2	9.5

Table 1.13 VIBHA's financial ratio – Risk Financial Indicators for VIBHA

Liquidity risk	2017	2016	2015	2014	2013
Current Ratio (CR)	0.41	0.32	0.44	0.45	0.61
Quick Ratio (QR)	0.27	0.23	0.27	0.26	0.29
Receivable Collection Period (RCP)	31	31	33	32	27
Inventory Conversion Period (ICP)	13	13	14	15	15
Payables Deferral Period (PDP)	27	27	28	28	29
Cash Conversion Cycle (CCC)	18	17	19	20	14

Solvency risk	2017	2016	2015	2014	2013
Debt -to-Equity ratio (DE)	48.6%	39.6%	43.5%	44.8%	40.5%
Debt-to-Total Assets ratio (DTA)	29.5%	25.2%	26.8%	27.2%	25.1%
Interest coverage ration (ICR)	9.22	9.97	11.71	10.53	11.98

In view of liquidity risk, BCH's current ratio and quick ratio are greater than VIBHA so BCH is higher liquidity because they have higher current assets than VIBHA. However, BCH's CCC is higher than VIBHA due to more account receivables and inventories. Although the payables of BCH are a bit higher than VIBHA. The BCH's inventories and payables are closed to VIBHA. The major components of CCC are receivables. Mostly, account receivables of BCH are Social Security Office and National Health Security Office that are credibility to pay back. Moreover, the main items of inventories are medicine and medical supplies which is quite high turnover. For solvency risk, BCH's DE ratio and DTA ratio are higher than VIBHA due to high debt in 2017 for investment in 5 new projects. However, BCH has ICR as 11.2 which is greater than VIBHA as 9.22 that shows the higher ability to pay back their interest expenses.

Table 1.14 BCH's forecast financial ratio 2018-2022

Forecast Financial Ratio 2018-2022

Ratio	2017	2018F	2019F	2020F	2021F	2022F
Profitability						
Operating profit margin	20%	19%	22%	26%	28%	29%
Net profit margin	15%	15%	17%	20%	22%	23%
ROA	10.80%	10.84%	12.94%	16.83%	19.66%	21.78%
Profit Margin (PM)	16.82%	16.65%	18.23%	21.66%	23.39%	24.24%
Tax Change (TC)	1	1	1	1	1	1
Tax Management (TM)	1.03	1.02	1.02	1.01	1.01	1.01
Total Asset TurnOver (TATO)	0.62	0.64	0.70	0.77	0.83	0.89
ROE	22.31%	19.71%	21.90%	27.70%	29.06%	28.19%
ROA	10.80%	10.84%	12.94%	16.83%	19.66%	21.78%
Earning Leverage (EL)	0.91	0.92	0.92	0.95	0.96	0.97
Capital Structure Leverage (CSL)	2.07	1.98	1.83	1.74	1.54	1.34
Liquidity & Financial Leverage	21 21 -					
Current Ratio (CR)	1.48	0.85	0.89	0.99	1.11	1.25
Quick Ratio (QR)	1.39	0.85	0.89	0.98	1.11	1.25
Debt -to-Equity ratio (DE)	92.9%	62.0%	61.6%	45.3%	25.3%	8.4%
Debt-to-Total Assets ratio (DTA)	43.4%	33.8%	33.7%	27.3%	17.5%	6.7%
Interest coverage ration (ICR)	11.2	12.3	13.2	19.1	24.4	29.0

1.6.4 Forecast financial ratio 2018-2022

1.6.4.1 Profitability margins improve by solid operations

According to the forecast financial ratio 2018-2022, the operating profit margin and net profit margin continuously increase because of the strategies to create the solid operations. Especially, the utilization rate of OPD and IPD raise over the years of KH and KV from improving the standard and quality services and expansion new hospitals. Additional quota of social security scheme for existing and new hospitals influent to create higher performance. The better performance from WMC also enhance the BCH the higher operating profit margin and net profit margin. Moreover, the macro environment favors BCH which generate improving in solid operations.

1.6.4.2 Stronger financial ratio for return and risk ratios

BCH has remained strong financial performance as ROA and ROE increasing over the years. In term of ROA, the main item to support the higher ROA is profit margin (PM). The profit margin raise because the higher revenue is more than increasing in cost. BCH can increase the utilization rate as well as efficiently control its cost. The current ratio and interest coverage ratio of BCH is stronger than the competitor. For the outlook of the company's financial position, BCH is expected to become much more solid with higher lower risks from debt level. Although the current

ratio expected to a bit lower which come from the higher in non-current asset from expansion strategies. In term of debt ratio, they expected to decrease over the years because of the lower interest-bearing debt level. In addition, the interest coverage ratio tends to increase over the years. With the higher performance, BCH can generate more cash from operating activities to repay debt and interest expense.

1.7 Investment Summary

The recommendation is BUY for Bangkok Chain Hospital Public Company Limited (BCH) with end of 2018 target price of THB 20.22 using Relative Valuation Method. This offer a 15% upside from its closing price of THB 17.50 on 20 November 2018. BCH has fascinating future from its core business and revenue likely to hit the new high record, WMC has turned to report a strong profit, growth from investments in new hospitals which most of them will start services in 2020.

1.7.1 Profit will hit new high record in 2019

Revenue expected to rise by 14%. The expectation come from both higher OPD and IPD patients. The number of cash patient local will rise 3.9% based on the company CAGR. The bed days utilization rate will increase from 40% in year 2018 to 42% in year 2019. The price for OPD and IPD are expected to be in line with Thailand inflation which is 2.5%. The quota for social security patients will increase by 57,000 or 4.8% from BCH's three main hospitals at Prachachuen, Bangkae and Rattanathibet. Moreover, the number of Thai patients will increase along with domestic consumption remains strong and serve as an important key to drive domestic economy. The 15 months of annual check-up services for personnel under the Ministry of Education start in 4Q18 will also boost revenue for full year in 2019.

1.7.2 Rising of World Medical Center (WMC) performance

WMC made its first quarterly net profit in 2Q18, it took five years since it opened and the revenues jumped 78% with 118% year-over-year increase in foreign patient revenues and 33% year-over-year increase in Thai patient revenues. The

improvement mainly come from the increase in utilization rate of IPD. The foreign patients make significant impact as the hospital charge higher price than Thai patients do. BCH also works with agents to bring foreign patients. This will strengthen the revenue of WMC. The revenue contribution of WMC increase from 6.40% in 2016 to 7.82% in 2017. WMC generate higher margins than its mid and low end hospitals as it focuses more on foreign patients after recent specialized clinics are build.

1.7.3 Open Kasemrad hospital Ramkhamhaeng in Q4 2018 and three greenfield hospitals over the next three years

Kasemrad hospital Ramkhamheang (139 IPD beds) is used to transfer patient from Karunvej Sukhapiban 3 (100 beds, close 2018 yearend). The transition has been smooth, result in Kasemrad hospital Ramkhamheang can perceive the revenue immediately. The rest of hospitals are Kasemrad Sa Kaeo (115 beds), Kasemrad Prachiburi (116 beds) and Kasemrad international hospital (250 beds). These offer the opportunity to receive new patients from both OPD and IPD as well as social security patients. Moreover, the social security scheme patients can increase from 2 new hospitals is expected about 70 thousand people.

1.8 Valuation

1.8.1 Pro Forma analysis

Revenue from hospital operation

The method of calculation the revenues of hospital base on the research from Hospital valuation in emerging countries of MIT and general practice of many private hospitals which shown in the presentations to shareholder meeting and annual reports.

1.8.1.1 Segmentation

The revenue from hospital operation can be decomposed into 2 groups of revenue because revenue from WMC concentrate on high-end and international patients but revenue from KIH, KH and KV concentrate on middle to high income patients. Therefore, the forecast of revenue divided into 2 groups and base on different assumptions for quantity and price.

Table 1.15 Revenue by segments

1. Revenue Breakdown					
1.1 Revenue Breakdown b	y type of patients				
		Average			
		portion	2015	2016	2017
WMC		6.54%	5.40%	6.40%	7.82%
Kasemrad		82.89%	83.80%	83.40%	81.46%
Karunvej		10.57%	10.80%	10.20%	10.72%
		Source from BC	CH Presentation in A	Analyst conferenc	e Y2015-Q2'20
1.2 Revenue Breakdown b	y type of patients				
WMC		Average			
WMC		portion	2015	2016	2017
Cash patient-(Walk-in) - %	Utilize rate by cate	100%	100%	100%	100%
OPD-TH	81%	44%	52%	42%	39%
OPD-FN	19%	10%	11%	11%	99
IPD-TH	65%		29%	26%	32%
IPD-FN	35%	17%	8%	21%	20%
Cash patient-(Walk-in) - MB			2015	2016	2017
	OPD		196	221	272
	IPD		115	196	295
Kasemrad & Karunvej		Average	2015	2016	2017
Cash patient-(Walk-in) - %		63%	65%	64%	62%
•	OPD	36%	38%	36%	36%
	IPD	27%	27%	28%	26%
Social security scheme		36%	34%	35%	37%
Universal Coverage		1%	1%	1%	1%
Cash patient-(Walk-in) - MB	OPD	2,125	1,975	2,094	2,306
	IPD	1,562	1,454	1,630	1,603
Social security scheme		2,328	1,963	2,305	2,717
Universal Coverage		63	63	65	62
		Source from BC	CH Presentation in /	Analyst conference	e Y2015-2017

1.8.1.2 Quantity

The patients type can be categorized into OPD and IPD. Apply the number of visits per day and bed days to identify capacities of the company after that made the calculation for utilization rate of OPD and IPD respectively. The first step is calculation historical utilization rate per year of OPD and IPD as the total capacity per year divide with actual number of visits per year or bed year. In term of WMC, the benchmark is BH because BH is a premium hospital, mainly serve high-end and international patients similarly to BCH. Moreover, BH was in the mature stage so assumed that WMC would have the same utilization rate as BH in the future. The data collect from the past revenue of BH about 20 years ago found that BH had the stable revenue growth rate in 2016. BH took about 17 years to mature stage. Therefore, assume that utilization rate of WMC will be close to BH at the same period. The target growth of utilization rate of WMC for OPD and IPD will use BH's rate and proportionate of the target growth rate with mature stage of BH, 17 years that come from BH's mature stage as below figure.

Table 1.16 Quantity of WMC

	CAGR	2015	2016	2017					
Number of visits	1.27%	62,000	59,000	64,400					
mber of visits per day	1.27%	170	162	176					
bed days	15.05%	4,400	6,100	6,700					
				2017	2018	2019	2020	2021	2022
Operation	beds			150	150	150	150	150	150
umber of beds * 365	365	days							
Full capacity	CAGR	2015	2016	2017	2018	2019	2020	2021	2022
613,200	1.27%	10%	10%	11%	13%	16%	18%	21%	23%
54,750	15.05%	8%	11%	12%	16%	19%	22%	26%	29%
) times per room per da	ay								
		Target Utilizati	on rate comp	ared with BH	2018	2019	2020	2021	2022
				OPD-TH	64,873	77,582	90,290	102,999	115,708
				OPD-FN	15,217	18,198	21,179	24,160	27,141
				IPD-TH	5,536	6,739	7,942	9,145	10,348
				IPD-FN	3,025	3,682	4,339	4,997	5,654
u	Operation mber of beds * 365 Full capacity 613,200 54,750	Number of vists beer day bed days 15.05% Operation beds	Number of vists 1.27% 62,000 her of vists per day 1.27% 170 bed days 15.05% 4,400 Operation beds mber of beds * 365 365 days	Number of vists 1.27% 62,000 59,000 her of vists per day 1.27% 170 162 bed days 15.05% 4,400 6,100 Operation beds mber of beds * 365 365 days	Number of vists 1.27% 62,000 59,000 64,400 her of vists per day 1.27% 170 162 176 hed days 15.05% 4,400 6,100 6,700 Operation beds	Number of vists 1.27% 62,000 59,000 64,400 her of vists per day 1.27% 170 162 176 15.05% 4,400 6,100 6,700 150 150 150 150 150 150 150 150 150 1	Number of vists 1.27% 62,000 59,000 64,400 her of vists per day bed days 15.05% 4,400 6,100 6,700 150 150 150 150 150 150 150 150 150 1	Number of vists 1.27% 62,000 59,000 64,400 her of vists per day 1.27% 170 162 176 her of vists per day 15.05% 4,400 6,100 6,700 150 150 150 150 150 150 150 150 150 1	Number of vists 1.27% 62,000 59,000 64,400




Figure 1.24 Quantity of WMC - OPD




Figure 1.25 Quantity of WMC – IPD

In term of KIH, KH and KV, divide in to 3 types of patients as OPD-cash patients, IPD-cash patients and Social security scheme. The quantity of OPD-cash patient come from the capacities base on examination rooms and add up the new capacity of 5 new hospitals in each year. After that calculate the utilization rate and assume the rate to grow as historical CAGR of utilization rate. For IPD-cash patients, also take into account of opening 5 new hospitals in 2018-2020 so add up the new capacity (beds) in each year that plan to operate. The quantity of IPD comes from the utilization rate with new capacity that grow up by historical CAGR. For social security scheme, the data collected from the SC quota as figure below shown in Analyst Presentation in March 2018. The additional data is 140 thousand people and add up the new quota of new hospitals which receive social security scheme about 210 thousand people. The additional quota will equally add up to existing quota in forecasting period.

Table 1.17 Quantity of KH & KV

Capacity																	
Cash patient-(Walk-in)			2017	2018	2019	2020	2021	2022									
OPD	Exam rooms	rooms	330	340	374	447	469	469									
IPD	Operation	beds	2,028	2,063	2,197	2,526	2,682	2,682	SC	Years							
Kasemrad Hospital Ramkamhang	In Q4 2018	139	39						70,000	5							
Kasemrad Hospital Chiang-Khong	In Q1 2019	30	5														
Kasemrad Hospital Sakaeo: 115 l	In Q1 2020	115	36														
Kasemrad Hospital Prachinburi: 1:	In Q2 2020	116	29						140,000	3							
Kasemrad International Hospital \	In Q3 2020	254	30						,								

Kasemrad & Karunvej		CAGR	2013	2014	2015	2016	2017	2018 2019 2020 2021				
Cash patient-(Walk-in)												
OPD	Number of visits	3.90%	2,640,000	2,700,000	2,750,000	3,005,000	3,200,000	3,426,290	3,916,752	4,862,149	5,304,515	5,512,580
IPD	bed days	6.60%	200,500	200,000	240,000	250,000	276,500	299,946	340,635	417,647	472,880	504,274
Social security scheme	Number of registered pers	5.50%	608,561	672,112	681,506	748,089	793,671	825,171	867,171	944,171	1,032,838	1,121,504
-									Quota :	140K+New Pro	jects	
Utilization rate								327,833				
Cash patient-(Walk-in)	Full capacity'17	CAGR	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
OPD*	9,636,000	3.92%	27%	28%	29%	31%	33%	35%	36%	37%	39%	40%
IPD - bed days	740,220	6.64%	27%	27%	32%	34%	37%	40%	42%	45%	48%	52%
_	* 80 times per room per day Number of beds * 365											



Figure 1.26 Quantity of KH & KV – OPD



Figure 1.27 Quantity of KH & KV – IPD




Figure 1.28 Quantity of KH & KV – SS

1.8.1.3 Price

The price of WMC can be decomposed into 4 groups as OPD-Foreign, OPD-Thai, IPD-Foreign and IPD-Thai assume to grow by CAGR.

Table 1.18 Price of WMC

3. Price			100				- 10		
WMC				Forecast: High growth period					
Revenue (unit: MB)	CAGR	2015	2016	2017	2018	2019	2020	2021	2022
Cash patient-(Walk-in):									
OPD-TH	4.54%	2,635	2,720	3,010	3,147	3,289	3,438	3,594	3,757
OPD-FN	17.31%	6,250	8,180	10,090	11,837	13,886	16,289	19,109	22,417
IPD-TH	15.91%	19,632	20,889	30,575	35,441	41,081	47,618	55,196	63,980
IPD-FN	9.41%	51,531	47,530	67,487	73,836	80,783	88,383	96,699	105,796




Figure 1.29 Price of WMC

The price of KIH, KH and KV assume to increase by inflation rate because CAGR is quite low since the company maintain a competitive price excepting social security scheme. Assume the price of social security scheme will be stable for conservative method because of limited budget allocation to the hospitals in the scheme by the Social Security Office (SSO).

Table 1.19 Price of KH & KV

Kasemrad & Karunvej			460		90		1111			
Revenue (unit: MB)			2015	2016	2017	2018	2019	2020	2021	2022
Cash patient-(Walk-in): In	iflation rate	2.50%								
	OPD	0.11%	718	697	721	739	757	776	795	815
	IPD	-1.45%	6,058	6,521	5,797	5,942	6,091	6,243	6,399	6,559
Social security scheme		5.92%	2,881	3,081	3,423	3,423	3,423	3,423	3,423	3,423




Figure 1.30 Price of KH & KV

The forecasted revenue of all types of patient would come from quantity multiply with price as below figures. The forecasted revenues have CAGR of 11.66% which quite reasonable since it is in range of the management expectation as 10-15% from 2018-2022 in annual report 2017.

Table 1.20 BCH's Forecast revenue from hospital operation

3. Revenue: Volumn*Price			Forecast						
				Hi	gh growth peri	od			
Revenue (unit: MB)	CAGR	2017	2018	2019	2020	2021	2022		
Cash patient-(Walk-in): Times of services									
OPD-WMC	25.1%	272	384	508	655	832	1,043		
OPD-KH	11.8%	2,306	2,530	2,965	3,773	4,219	4,494		
IPD-WMC	27.4%	295	420	574	762	988	1,260		
IPD-KH	12.8%	1,603	1,782	2,075	2,607	3,026	3,308		
Social security scheme: Number of registered persor	5.9%	2,717	2,825	2,968	3,232	3,535	3,839		
Total Revenue	11.66%	7,193	7,941	9,090	11,029	12,600	13,944		

1.8.1.4 Cost from hospital operation

Cost from hospital operation can be divided into 2 types as variable and fixed cost. Medical and supply costs and Doctor Fee are classified to variable cost which appropriately grow with percentage of revenue from hospital operations. The remaining cost are classified into fixed cost because they don't change with an increase or decrease in the number of services. For personal expenses, it relates to personnel including salary, benefits, trainings, and payroll taxes incurred by the organization during the reporting period. The mainly item is salary of hospital staffs. Therefore, forecasted personal expenses come from growth of salary rate increase in

Thai at 5.5% from Willis Towers Watson who conducted a survey in Thailand with key industries. The other costs are depreciation and amortization, utility expenses and other. For depreciation and amortization, growth rate as a percentage of PPE is used and other costs assume to equal to inflation rate.

Table 1.21 BCH's Forecast cost from hospital operation

1.1 Cost of hospital operations B												
	CAGR Methods sumpti				2015	2016	2017	2018	2019	2020	2021	2022
Variable Cost												
		% of Revenues from hospital										
Medical and supply costs	6%	operations	19%	1,081	1,092	1,247	1,347	1,530	1,751	2,124	2,427	2,68
		% of Revenues from hospital										
Doctor fee	5.95%	operations	19.74%	1,098	1,130	1,276	1,384	1,568	1,795	2,178	2,488	2,75
Fixed Cost												
Personal expenses	8%	Salary rate increase in Thai	5.5%	916	1,054	1,139	1,244	1,313	1,385	1,461	1,542	1,6
Depreciation and amortization	6%	CAGR > % of PPE	6%	346	369	412	430	467	540	571	581	5
Utility expenses	1%	Expected Inflation Rate	2.50%	138	144	176	141	145	148	152	156	10
Other	38%	Expected Inflation Rate	2.50%	91	200	224	330	338	347	355	364	3
Total	7%	CAGR	9%	3,670	3,989	4,472	4,877	5,360	5,966	6,842	7,558	8,19
		Expected Inflation Rate	2.50%									

1.8.2 Relative valuation

The valuation of BCH determines based on relative valuation method by using five multiples: Trailing P/E, Forward P/E, P/BV, Trailing EV/EBITDA and Forward EV/EBITDA. Using these five multiples, the valuation come out for five target prices. After made the comparison, the Forward EV/EBITDA is selected as a multiple for calculate target price of BCH because the nature business of hospital always has to invest in large amount of equipment, tools and building. These transactions have to record high depreciation and amortization which reduce the net profit. However, depreciation and amortization is non-cash transaction that the company do not actually pay. To find the total value of the BCH, these non-cash record have to add back to determine BCH target price. Therefore, EV/EBITDA is used to account for free cash flow. The forward is chosen to determine the future value of company instead of trailing. Forward uses future EBITDA estimated which is more useful than trailing which is the past EBITDA.

1.8.2.1 Ratio bands

First, start with plotting Trailing and Forward P/E bands, Trailing and Forward PBV bands, Trailing and Forward EV/EBITDA bands. These bands are based on 5 years past history. In relation to itself, BCH is undervalued by Trailing P/E band and overvalued by Forward P/E band. BCH's current trailing P/E is between minus one standard deviation and median, below its 5-year median. BCH's Forward P/E is

greater than 1 standard deviations and above its 5-year average. For Trailing PBV, it is overvalued and stay between + 2 standard deviations and +1 standard deviation. It is the same for Forward PBV band. Next BCH current trailing EV/EBITDA is between +1 standard deviation and median, above its 5-year median. BCH's Forward EV/EBITDA is greater than +1 standard deviations but below +2 standard deviations.




Figure 1.31 Trailing P/E band




Figure 1.32 Forward P/E band




Figure 1.33 Trailing PBV band



Figure 1.34 Forward PBV band




Figure 1.35 Trailing EV/EBITDA band




Figure 1.36 Forward EV/EBITDA band

Source: Reuters & Group Calculations

The using of ratio band can help estimate share price based on the past historical performance by multiplying the ratio with expected EBITDA as shown in the table below.

Table 1.22 Estimate target price from Forward EV/EBITDA band

				Forv	ward EV/EBI	ITDA	
			-2SD	-1SD	Median	+1SD	+2SD
		THB	11.5 x	14.4 x	17.2 x	20.1 x	23 x
	20%	4,232	17.9	22.8	27.5	32.4	37.4
	10%	3,879	16.2	20.7	25.1	29.6	34.1
EBITDA	Base case	3,527	14.6	18.7	22.7	26.8	30.9
	-10%	3,174	13.0	16.7	20.2	23.9	27.6
	-20%	2,821	11.3	14.6	17.8	21.1	24.4

1.8.2.2 Group of peers

Determined a group of peers to compare BCH, by comparing on EBITDA margin debt-to-equity, ROE, and others. After looking at many companies, 5 comparable firms are selected to compare with BCH.

Table 1.23 BCH's comparable firms and their ratios

Peers Name	Ticker	Market Cap	Price	P/E	P/ FY2		P/E FY2019	P/B	EV/EBITDA	EV/EBITDA FY2018	EV/EBITDA FY2019
BANGKOK CHAIN HOSPITAL PCL	BCH	43,641	17.50	39.7	40	.3	34.6	8.0	21.5	21.0	18.7
BANGKOK DUSIT MED SERVICE	BDMS	395,557	25.25	40.0	39	.5	35.3	5.7	24.4	24.4	21.8
BUMRUNGRAD HOSPITAL PCL	BH	135,183	185.50	33.0	32	.4	31.6	7.7	20.9	20.9	19.5
VIBHAVADI MEDICAL CENTER PCL	VIBHA	29,303	2.22	34.9	31	.7	27.8	4.1	22.2	20.7	18.2
THONBURI HEALTHCARE GROUP PC	THG	28,387	31.75	44.1	41	.3	32.6	3.2	-	24.4	19.7
CHULARAT HOSPITAL PCL	CHG	22,440	2.04	34.6	32	.4	28.7	6.5	21.7	20.9	19.0
Median				34.9	32	.4	31.6	5.7	21.9	20.9	19.5
Average				37.3	35	.5	31.2	5.4	22.3	22.3	19.6

1.8.2.3 Valuation estimation

The forecasted EPS and EBITDA for BCH acquire from proforma income statement for future years. For revenue growth rate, calculate base on the research from Hospital valuation in emerging countries of MIT and general practice of many private hospitals which shown in the presentations to shareholder meeting and annual reports. For the fiscal year 2018, projected a profit of 996 million THB and EBITDA of 2,096 million THB. For fiscal year 2019, projected a profit of 1,296 million THB and EBITDA of 2,575 million THB.

Table 1.24 Pro-forma

Year		1	2	3	4	5
Teal	2017	2018	2019	2020	2021	2022
Revenues from hospital operations	7,255	7,941	9,090	11,029	12,600	13,944
Other Income	107	109	113	116	119	123
Total Revenues	7,361	8,051	9,203	11,145	12,720	14,067
Cost of hospital operations	4,877	5,360	5,966	6,842	7,558	8,190
Distribution costs	120	99	113	137	157	173
Administrative expenses	840	941	1,054	1,180	1,322	1,481
Total Expenses	5,836	6,399	7,133	8,159	9,036	9,844
Share of profit of investment in associate	1	1	1	1	1	1
EBIT	1,526	1,652	2,071	2,987	3,685	4,225
Finance Charges	136	126	147	147	141	136
EBT	1,390	1,526	1,924	2,840	3,543	4,088
Taxation	271	305	385	568	709	818
Net profit	1,119	1,221	1,539	2,272	2,834	3,270
Non-controlling interests	202	218	236	255	275	298
Profit for the year: Owners of the company	917	1,003	1,304	2,017	2,559	2,973
Number of weighted average common shares (shares)	2,493,748	2,493,748	2,493,748	2,493,748	2,493,748	2,493,748
EPS	0.37	0.40	0.52	0.81	1.03	1.19
Depreciation	463	444	504	540	564	589
EBITDA	1,988	2,096	2,575	3,527	4,249	4,814

As the quarter three 2018 earning already announce. Compare with projection at the end of year 2018 and calculate for last quarter base on pro-forma. The calculation based on pro-forma is used to calculate for multiple valuation by

multiplying them with median peer ratio to arrive at target prices for BCH shares. The latest book value from Q3, 2018 which is 6,102 THB million is used. From trailing P/E, the target price for year end 2018 and 2019 are 14.0 and 18.2 respectively. Using Forward P/E, the determination price is 16.9 for year end 2018 and 25.6 for year-end 2019. The PBV provide target price of 14.0 at the end of year 2018. For Trailing EV/EBITDA method, arrive at target price of 17.1 and 21.1 for year end 2018 and 2019. Lastly, Forward EV/EBITDA calculation indicate target price of 20.2 for year end 2018 and 26.0 for year-end 2019.

Table 1.25 Relative valuation summary

//_5	2017A	2018 1QA-3QA	2018 4QF	2018F	2019F	2020F
EPS	0.37	0.33	0.07	0.40	0.52	0.81
EBITDA	2,064	1,667	430	2,096	2,575	3,527
Non-operating Assets	i 	501		721	820	880
Value of Debt	 	4,651		4,120	4,672	4,050
BookValue (3Q2018)		6,102				
Relative valuation Trailing P/E				14.0	18.2	
Forward P/E				16.9	25.6	
P/BV	 			14.0		
Trailing EV/EBITDA				17.1	21.1	
Forward EV/EBITDA				20.2	26.0	
Average	 			17.1	24.2	_

1.8.2.4 Valuation recommendation

The recommendation based on relative valuation is Buy. Base on Forward EV/EBITDA of THB 20.2 for year end 2018 and THB 26.0 for year-end 2019. This offer 15% upside for year end 2018 and 49% upside for year 2019 based on closing price of THB 17.5 on 20 November 2018. The EV/EBITDA is selected as a main multiple to represent target price of BCH because the nature business of hospital always has high depreciation and amortization which is non-cash transaction but subdue the

profit of the company. This make EV/EBITDA suit to calculate for target price as it accounts for non-cash transaction. Lastly, the forward is suitable for calculate future price rather than trailing to determine company future valuation.

1.8.2.5 Rating criteria

According to the common industry procedure, to provide the recommendation on target stock, the decision based on rating criteria and divided into 3 categories. Firstly, if the value per stock is upside more than 10% from current price, the BUY recommendation issued. Secondly, if the value per stock is upside in range - 10% to 10% the HOLD recommendation issued. Thirdly, if the value per stock is 10% downside from current price, the SELL recommendation issued.

Table 1.26 Rating Criteria

Rating Rules:	A A
Buy	10% or Greater Upside
Hold	Less than 10% upside and greater than 10% downside
Sell	Lower than 10% downside

1.8.2.6 Sensitivity analysis

To ensure the valuation, sensitivity analysis of EBITDA is demonstrated as below figures to show the potential share price.

Based on the sensitivity analysis, the expected share price is THB 20.2. Referring to the sensitivity, the possible range of EBITDA is 20% gap deviate from base case. The target price will change according to EBITDA.

Table 1.27 Sensitivity analysis – EBITDA

		Forward
		EV/EBITDA
	EBITDA	2018F
	THB	20.9 x
20%	3,090	24.5
10%	2,832	22.4
Base case	2,575	20.2
-10%	2,317	18.1
-20%	2,060	15.9

1.9 Investment Risks and Downside Possibilities

The accession for related risk which generate downside possibilities for BCH as following;

Risk Matrix Limitation of the The competition in numbers of private hospital expertise in medical industry profession High The regulatory changes on managed care Economic downturn programs **Impact** The consumer behavior High Working capital and CAPEX Low Likelihood High Low

Figure 1.37 Risk matrix

1.9.1 The competition in private hospital industry

The competition in private hospital continually increase over the years. For the KH and KV brand, BCH maintains their service rate to be competitive price. Moreover, the company provide full range of medical services as center of excellences to create uniqueness and increase competitiveness. As a chained hospital, the company take advantage from cost effective procurement through central procurement department to be competitive cost. In term of the business plan, the company will expand into strategic locations to serve new potential patients.

1.9.2 Limitation of the numbers of expertise in medical profession

The number of medical profession are widely recognized are insufficient to serve the increasing demand. So each private hospitals competes with the high rate for remuneration that make the costs of human resource to be even higher. As the below figure, the healthcare supply in Thailand in 2016 shown that there are 5 doctors, 24 nurses and 22 beds per 10,000 populations in Thailand. Nowadays, the cost of human considers as one of the key considerations for private hospital. BCH provide competitive remuneration package as employee's welfare program and training course to retain the physicians and staffs. Moreover, their employees can participate in management discussions so they can be a part of the business growth. Therefore, the doctor fee and personal expenses would be increase as presented in scenario analysis for cost of hospital.

Healthcare Supply in Thailand (2016)									
(Number per 10,000 population)	Thailand	Global*							
Doctor	5	14							
Nurse	24	30							
Bed	22	26							

Figure 1.38 Healthcare supply in Thailand (2016)

1.9.3 The regulatory changes on managed care programs

BCH had the revenue from Social Security Scheme about 37% of the total revenue in 2017. Therefore, regulatory changes could affect the business operations. However, the management always monitors the changes and actively engages in the policy setting discussion as well as providing the necessary information to the Government Agencies Committee. In addition, the company has the policy to control its expenditures and always evaluate the change of aforementioned managed care program to decrease the downside possibilities which will be effect the company's performance.

1.9.4 Economic downturn

According to GDP of quarter 3 of 3.3% from NESDB which slightly decrease from previous quarter of 4.6%. From the economic outlook of NESDB, it tends to slightly grow to 4.2% in 2019 and 4.5% in 2020. The government announced the new election in 2019 so the possibility that the economic would be downturn is quite low. If it occurs, it would impact to private hospital as lower revenue because the people would tend to choose the public hospital to apply the 30 Baht Health Care Scheme. However, BCH secures their revenue by Social Security Scheme about 37% of total revenue.

1.9.5 The consumer behavior

Normally, the patients tend to choose the hospital with experiences of an individual physician and expertise. Therefore, the new established hospitals would take longer time to generate their reputation for quality of service. BCH has a plan to generate the strong brands for each type of patients such as WMC for high end and international patients and KH and KV for medium and social security scheme patients. The new hospitals also create strong brands for specific types of customers for example Kasemrad Hospital Prachinburi which located near Rojana industrial estate intend to serve social security scheme patients.

1.9.6 High Working capital and CAPEX

The mainly item for working capital of BCH is trade account receivable of BCH which are quite high of 1,054 MB or 8% of total assets that mainly comes from Social Security Office and National Health Security Office with 78% less than 3 months. However, in 2017, BCH already has submitted the letter to Social Security Office which was during the process to follow up the collectability of the remaining that certain subsidiaries had partial receipt. Moreover, Social Security Office and National Health Security Office are credibility to pay back.

In term of CAPEX, the projects for new hospital require huge investment in land, building, human resources, medical equipment, medicine, medicine supplies and consumables. The company plan to establish the 5 new hospitals which they finance from debt by issuing company bonds and long-term borrowings from financial institutions with quite low interest rate. However, current ratio and quick ratio of BCH

are quite high because they has higher current assets and BCH's CCC is also high. Moreover, BCH has high ICR as 11.2 that shows the higher ability to pay back their interest expenses.

1.9.7 Scenario analysis

Scenario analysis can predict mainly 2 risks that would impact the value of BCH. Firstly, the competition in private hospital industry is high likelihood because it is the current situation in private hospital industry and generate high impact to sales of BCH. The second one is the limitation of the numbers of expertise in medical profession which also high impact to cost of BCH and tends to be medium likelihood because BCH provide competitive remuneration package as employee's welfare program and training course to retain the physicians and staffs. Therefore, identify the driver of sales and costs variables which mainly affect to the target price as the sensitivity spider chart. Refer to the chart, the key variables are growth rate of utilization rate of OPD and IPD for KH and KV and price for all categories excepted WMC's OPD price for Thai patients and cost of three types because they are quite steeply slope due to high range in price gap. With the scenario analysis, the expected share price is THB 20.2.

In term of scenarios analysis, divide into two scenarios by changing variables of revenues and cost as below figures.




Figure 1.39 Sensitivity Spider Chart

Table 1.28 Sensitivity Spider Chart

% Change from Base	OPD- WMC_TH	ate_OPD-	ate_IPD-	_growui_r	OPD-	Utilization_ growth_rat e_IPD- KH&KV	h_rate_OPD	OPD-	wth_rate_I	wth_rate_I PD-	wth_rate_	Price_gro wth_rate_I PD- KH&KV	supply	Cost_Pers onal	Cost_Doct or fee
-20%	20.136	20.170	20.095	20.179	20.035	20.006	20.186	20.099	20.097	20.138	19.981	20.053	23.158	20.464	23.232
-10%	20.179	20.196	20.159	20.201	20.129	20.114	20.204	20.161	20.159	20.180	20.102	20.138	21.691	20.343	21.727
0%	20.223	20.223	20.223	20.223	20.223	20.223	20.223	20.223	20.223	20.223	20.223	20.223	20.223	20.223	20.223
10%	20.266	20.249	20.287	20.245	20.316	20.331	20.241	20.286	20.287	20.266	20.344	20.308	18.755	20.101	18.718
20%	20.309	20.276	20.351	20.266	20.410	20.439	20.260	20.350	20.352	20.309	20.466	20.393	17.287	19.979	17.213
Range	0.1731	0.1059	0.2563	0.0875	0.3753	0.4332	0.0743	0.2501	0.2549	0.1715	0.4850	0.3394	5.8717	0.4843	6.0189

Table 1.29 Scenario Analysis for Revenue

		BUY Upside 40%	BUY Upside 32%	BUY Upside 24%	BUY Upside 16%	HOLD Upside 8%	HOLD Upside 0%	HOLD Downside -5%
Scenario Summary								
	Current Values:	Best case 3%	Best case 2%	Best case 1%	Base case	Worse case 1%	Worse case 2%	Worse case 3%
Changing Cells:								
Price_growth_rate_OPD_TH	4.5%	8%	7%	6%	4.5%	4%	3%	2%
Price_growth_rate_OPD_FN	17.3%	20%	19%	18%	17.3%	16%	15%	14%
Price_growth_rate_IPD_TH	15.9%	19%	18%	17%	15.9%	15%	14%	13%
Price_growth_rate_IPD_FN	9.4%	12%	11%	10%	9.4%	8%	7%	6%
Utilization_growth_rate_OPD	3.9%	7%	6%	5%	3.9%	3%	2%	1%
Utilization_growth_rate_IPD	6.6%	10%	9%	8%	6.6%	6%	5%	4%
Price_growth_rate_KH_OPD	2.5%	5.50%	4.50%	3.50%	2.5%	1.50%	0.50%	0.00%
Price_growth_rate_KH_IPD	2.5%	5.50%	4.50%	3.50%	2.5%	1.50%	0.50%	0.00%
Result Cells:								
Share_price	20.22	24.50	23.09	21.69	20.22	18.91	17.53	16.57

Table 1.30 Scenario analysis for Cost

		BUY Upside 31%	BUY Upside 26%	BUY Upside 20%	BUY Upside 16%	HOLD Upside 9%	HOLD Upside 3%	HOLD Downside -2%
Scenario Summary								
	Current Values:	Best case 3%	Best case 2%	Best case 1%	Base case	Worse case 1%	Worse case 2%	Worse case 3%
Changing Cells:								
Personal_expenses	5.5%	3%	4%	5%	5.5%	7%	8%	9%
Medical_and_supply_costs	19.3%	16%	17%	18%	19.3%	20%	21%	22%
Doctor_fee	19.7%	16%	17%	19%	19.7%	21%	22%	23%
Result Cells:								
Share_price	20.22	22.96	21.99	21.01	20.22	19.04	18.06	17.07

Based on above scenarios analysis in the above figures, found that revenue variables seem to be a very critical variable to target price as only small change by 1% affect the rating recommendation. The decreasing revenues by 1%, the target price decrease from THB 20.22 to THB 18.91. Therefore, it presented that revenues are the key variables to determine the competitiveness in the industry. In term of cost, the cost of hospital is highly affect from doctor fee, medical and supply cost and personal expenses. The increasing cost of hospital by 1%, the target price decrease from THB 20.22 to THB 19.04. In conclusion, decreasing in the drivers of revenue would tend to create downside possibility to share price of BCH.

CHAPTER II DATA

2.1 Financial statement analysis

2.1.1 Trend Analysis

Table 2.1 Trend Analysis

								Base year
Balance Sheet (Million Baht)	2017 CMS	CAGR	2017	2016	2015	2014	2013	2012
Assets	1.50/	400/	2250/	770/	020/	600/	4.4007	1000
Cash and Marketable Securities	16%		235%	77%	92%	69%	149%	1009
Accounts Receivable	8%	7%	130%	124%	134%	135%	95%	1009
Inventories	2%	5%	145%	138%	134%	126%	116%	1009
Other Current Assets	0%	-8%		1018%		791%	254%	1009
Total Current Assets	27%	8%	181%	104%	115%	104%	122%	1009
		0%						
Restricted deposits	0%	-54%	2%	2%	51%	104%	102%	1009
Property, Plant, and equipment, Net	61%	1%	156%	148%	144%	138%	149%	1009
Goodwill	3%	10%	211%	211%	211%	129%	129%	1009
Intangible assets	1%	17%	249%	248%	212%	152%	116%	100%
Deferred tax assets	0%	4%	150%	148%	195%	173%	121%	100%
Other non-current assets	0%		342%	365%	365%	727%	192%	100%
Total Non-Current Assets	73%		177%	164%	161%	153%	148%	100%
rotal non carrene rissess	7570	0%	17770	10170	10170	15570	11070	1007
Total Assets	100%	5%	178%	148%	149%	140%	141%	100%
Total 763CG	100 70	0%	170 70	110 /0	11570	11070	11170	100 //
		0 70						Base year
Liabilities and Shareholders' Equity	2017 CMS	CAGR	2017	2016	2015	2014	2013	2012
Short-term borrowings from financial institu			31%	17%	237%	145%	129%	100%
Trade accounts payable	4%		165%	149%	128%	122%	144%	100%
Payables for hospital equipment and medical			83%	37%	46%	52%	105%	100%
Current portion of long-term loans from fin			0%	0%	7%	7%	9%	100%
Current portion of finance lease liabilities	0%		0%	129%	621%	672%	724%	100%
Current income tax payable	1%		87%	48%	46%	45%	48%	100%
Accrued expenses	3%	2%	166%	171%	175%	162%	154%	100%
Deferred income	0%		35%	103%	110%	101%	104%	100%
Other current liabilities	0%		127%	147%	214%	330%	239%	100%
Total Current Liabilities	18%		148%	170%	198%	117%	118%	100%
		0%						
Long-term debt	34%	103%	317%	182%	183%	243%	244%	100%
Finance lease liabilities	0%	-100%	0%	0%	67%	398%	721%	100%
Non-current provision for employee benefit	1%	8%	162%	138%	132%	115%	112%	100%
Other non-current liabilities	0%	-19%	49%	27%	26%	40%	143%	100%
Total Non-Current Liabilities	35%	4%	296%	172%	174%	232%	242%	100%
		0%						
Total Liabilities	53%		221%	171%	186%	174%	180%	100%
		0%						
Paid-In Capital	20%		125%	125%	125%	125%	125%	1009
Premium on share capital	5%		100%	100%	100%	100%	100%	1009
Retained Earnings	3,0	0%	10070	10070	10070	10070	10070	1307
Appropriated – legal reserve	2%		125%	125%	125%	125%	115%	1009
	14%		229%	173%	123%	95%	75%	1009
Unappropriated Other components of equity	14%		229%	1/3%	123%	90%	/3%	1009
Other components of equity	4464	0%	1.4007	4240/	1200/	44407	1000	4000
Total Shareholders' Equity	41%		143%	131%	120%	114%	109%	1009
Non-controlling interests	6%		169%	136%	133%	125%	137%	1009
Total Liabilities and Shareholders' E	100%	5%	145%	131%	121%	115%	112%	1009

2.1.2 Common size

Table 2.2 Common Size

Common Size						
Income Statement	VIBHA 2017	2017	2016	2015	2014	2013
Revenues						
Revenues from hospital operations	100%	100%	100%	100%	100%	100%
Other incomes	5%	1%	2%	1%	2%	2%
Total Revenues	105%	101%	102%	101%	102%	102%
Expenses						
Cost of hospital operations	68%	67%	69%	69%	69%	68%
Distribution costs	0%	2%	1%	1%	1%	1%
Administrative expenses	15%	12%	11%	14%	12%	12%
Total expenses	84%	80%	82%	84%	83%	81%
Share of profit of investment in associate	3%	0.01%	0.02%	0.05%	0.00%	0.00%
	370	0.0170	0.0270	0.0570	0.0070	0.0070
Profit (loss) before finance costs and income tax expenses	24%	21%	20%	17%	19%	21%
Finance costs	3%	2%	2%	3%	3%	2%
Profit (loss) before income tax						
expenses	21%	19%	18%	15%	16%	19%
Income tax expense	3%	4%	3%	3%	3%	4%
Net profit (loss)	18%	15%	14%	12%	13%	15%
	1					
	VIBHA	1	11/ /	_ ///		
Balance Sheet	2017	2017	2016	2015	2014	2013
Assets						
Cash and cash equivalents	3%	4%	5%	6%	5%	10%
Current investments	0%	12%	2%	1%	1%	3%
				2.70		
70.0 17 770	20/-	90/-	00/-	1006	110/-	00/
Trade accounts receivable	3%	8%	9%	10%	11%	8%
Trade accounts receivable Other receivables	0%	0%	0%	0%	0%	0%
Trade accounts receivable	0% 2%	0% 0%	0% 0%			0% 0%
Trade accounts receivable Other receivables Short-term loans to related parties Inventories Other Current Assets	0%	0%	0%	0% 0%	0% 0%	0% 0% 2% 0%
Trade accounts receivable Other receivables Short-term loans to related parties Inventories	0% 2% 1%	0% 0% 2%	0% 0% 2%	0% 0% 2%	0% 0% 2%	8% 0% 0% 2% 0% 23%
Trade accounts receivable Other receivables Short-term loans to related parties Inventories Other Current Assets Total Current Assets	0% 2% 1% 0% 9%	0% 0% 2% 0% 27%	0% 0% 2% 0% 18%	0% 0% 2% 0% 20%	0% 0% 2% 0% 19%	0% 0% 2% 0% 23%
Trade accounts receivable Other receivables Short-term loans to related parties Inventories Other Current Assets Total Current Assets Restricted deposits	0% 2% 1% 0% 9%	0% 0% 2% 0% 27%	0% 0% 2% 0% 18%	0% 0% 2% 0% 20%	0% 0% 2% 0% 19%	0% 0% 2% 0% 23%
Trade accounts receivable Other receivables Short-term loans to related parties Inventories Other Current Assets Total Current Assets Restricted deposits Investment in associate	0% 2% 1% 0% 9% 0%	0% 0% 2% 0% 27%	0% 0% 2% 0% 18%	0% 0% 2% 0% 20%	0% 0% 2% 0% 19%	0% 0% 2% 0% 23% 0%
Trade accounts receivable Other receivables Short-term loans to related parties Inventories Other Current Assets Total Current Assets Restricted deposits Investment in associate Investment in subsidiaries	0% 2% 1% 0% 9% 0% 15% 0%	0% 0% 2% 0% 27% 0% 0%	0% 0% 2% 0% 18%	0% 0% 2% 0% 20% 0% 0%	0% 0% 2% 0% 19% 0% 0%	0% 0% 2% 0% 23% 0% 0%
Trade accounts receivable Other receivables Short-term loans to related parties Inventories Other Current Assets Total Current Assets Restricted deposits Investment in associate Investment in subsidiaries Other long-term investments	0% 2% 1% 0% 9% 0% 15% 0% 29%	0% 0% 2% 0% 27% 0% 0% 0%	0% 0% 2% 0% 18% 0% 0% 0%	0% 0% 2% 0% 20% 0% 0% 0%	0% 0% 2% 0% 19% 0% 0% 0%	0% 0% 2% 0% 23% 0% 0% 0%
Trade accounts receivable Other receivables Short-term loans to related parties Inventories Other Current Assets Total Current Assets Restricted deposits Investment in associate Investment in subsidiaries Other long-term investments Long-term loan to related party	0% 2% 1% 0% 9% 0% 15% 0% 29%	0% 0% 2% 0% 27% 0% 0% 0% 0%	0% 0% 2% 0% 18% 0% 0% 0% 0%	0% 0% 2% 0% 20% 0% 0% 0% 0%	0% 0% 2% 0% 19% 0% 0% 0% 0%	0% 2% 0% 23% 0% 0% 0% 0% 0%
Trade accounts receivable Other receivables Short-term loans to related parties Inventories Other Current Assets Total Current Assets Restricted deposits Investment in associate Investment in subsidiaries Other long-term investments Long-term loan to related party Investment properties	0% 2% 1% 0% 9% 0% 15% 0% 29%	0% 0% 2% 0% 27% 0% 0% 0% 0%	0% 0% 2% 0% 18% 0% 0% 0%	0% 0% 2% 0% 20% 0% 0% 0% 0% 0%	0% 0% 2% 0% 19% 0% 0% 0%	0% 2% 0% 23% 0% 0% 0% 0% 0% 0% 0%
Trade accounts receivable Other receivables Short-term loans to related parties Inventories Other Current Assets Total Current Assets Restricted deposits Investment in associate Investment in subsidiaries Other long-term investments Long-term loan to related party	0% 2% 1% 0% 9% 0% 15% 0% 29% 0% 2%	0% 0% 2% 0% 27% 0% 0% 0% 0%	0% 0% 2% 0% 18% 0% 0% 0% 0% 0%	0% 0% 2% 0% 20% 0% 0% 0% 0%	0% 0% 2% 0% 19% 0% 0% 0% 0% 0%	0% 2% 23% 0% 23% 0% 0% 0% 0% 0% 0% 74%
Trade accounts receivable Other receivables Short-term loans to related parties Inventories Other Current Assets Total Current Assets Restricted deposits Investment in associate Investment in subsidiaries Other long-term investments Long-term loan to related party Investment properties Property, Plant, and equipment, Net Goodwill Intangible assets	0% 2% 1% 0% 9% 0% 15% 0% 29% 0% 2% 39% 5%	0% 0% 2% 0% 27% 0% 0% 0% 0% 0% 51% 3% 1%	0% 0% 2% 0% 18% 0% 0% 0% 0% 0% 5% 70% 3% 1%	0% 0% 2% 0% 20% 0% 0% 0% 0% 0% 6%	0% 0% 2% 0% 19% 0% 0% 0% 0% 0% 0% 5% 2% 1%	0% 2% 23% 0% 23% 0% 0% 0% 0% 0% 0% 74% 2%
Other receivables Short-term loans to related parties Inventories Other Current Assets Total Current Assets Restricted deposits Investment in associate Investment in subsidiaries Other long-term investments Long-term loan to related party Investment properties Property, Plant, and equipment, Net Goodwill Intangible assets Deferred tax assets	0% 2% 1% 0% 9% 0% 15% 0% 29% 0% 2% 39% 5% 0%	0% 0% 2% 0% 27% 0% 0% 0% 0% 0% 51% 3% 1% 0%	0% 0% 2% 0% 18% 0% 0% 0% 0% 0% 5% 70% 3% 1% 0%	0% 0% 2% 0% 20% 0% 0% 0% 0% 6% 68% 3% 1%	0% 0% 2% 0% 19% 0% 0% 0% 0% 7% 69% 2% 1%	0% 2% 23% 0% 23% 0% 0% 0% 0% 0% 0% 1% 0% 2% 1%
Trade accounts receivable Other receivables Short-term loans to related parties Inventories Other Current Assets Total Current Assets Restricted deposits Investment in associate Investment in subsidiaries Other long-term investments Long-term loan to related party Investment properties Property, Plant, and equipment, Net Goodwill Intangible assets Deferred tax assets Other non-current assets	0% 2% 1% 0% 9% 0% 15% 0% 29% 0% 2% 39% 5% 0% 0%	0% 0% 2% 0% 27% 0% 0% 0% 0% 61% 3% 1% 0%	0% 0% 2% 0% 18% 0% 0% 0% 0% 6% 70% 3% 1% 0%	0% 0% 2% 0% 20% 0% 0% 0% 6% 68% 3% 1% 0%	0% 0% 2% 0% 19% 0% 0% 0% 0% 0% 0% 19% 1%	0% 2% 23% 0% 23% 0% 0% 0% 0% 0% 1% 0% 2% 1% 0%
Other receivables Short-term loans to related parties Inventories Other Current Assets Total Current Assets Restricted deposits Investment in associate Investment in subsidiaries Other long-term investments Long-term loan to related party Investment properties Property, Plant, and equipment, Net Goodwill Intangible assets Deferred tax assets	0% 2% 1% 0% 9% 0% 15% 0% 29% 0% 2% 39% 5% 0%	0% 0% 2% 0% 27% 0% 0% 0% 0% 0% 51% 3% 1% 0%	0% 0% 2% 0% 18% 0% 0% 0% 0% 0% 5% 70% 3% 1% 0%	0% 0% 2% 0% 20% 0% 0% 0% 0% 6% 68% 3% 1%	0% 0% 2% 0% 19% 0% 0% 0% 0% 7% 69% 2% 1%	0% 0% 2% 0% 23% 0% 0% 0%

Table 2.2 Common size (cont.)

	VIBHA	2047	2045	2045	204	2012
Liabilities and Shareholders' Equity	2017	2017	2016	2015	2014	2013
Short-term borrowings from financial						
institutions	7%	1%	1%	11%	7%	6%
Trade accounts payable	2%	4%	4%	3%	3%	4%
Payables for hospital equipment and						
medical instruments	0%	1%	0%	1%	1%	1%
Other payables	0%	0%	0%	0%	0%	0%
Short-term borrowing from related party	5%	0%	0%	0%	0%	0%
Current portion of long-term loans from						
financial institutions	5%	0%	0%	0%	0%	0%
Current portion of debentures	0%	8%	14%	8%	0%	0%
Current portion of finance lease liabilities	0%	0%	0%	1%	1%	1%
Current income tax payable	0%	1%	1%	1%	1%	1%
Accrued expenses	2%	3%	4%	4%	4%	3%
Deferred income	0%	0%	1%	1%	1%	1%
Other current liabilities	3%	0%	1%	1%	1%	1%
Total Current Liabilities	23%	18%	25%	29%	18%	18%
Long-term borrowings from financial						
institutions	11%	15%	0%	0%	0%	0%
Debentures	0%	20%	24%	24%	33%	33%
Finance lease liabilities	0%	0%	0%	0%	1%	2%
Non-current provision for employee benefit	1%	1%	1%	1%	1%	1%
Other non-current liabilities	4%	0%	0%	0%	0%	1%
Total Non-Current Liabilities	16%	35%	25%	25%	35%	37%
Total Liabilities	39%	53%	50%	54%	53%	55%
Issued and paid-up share capital	9%	20%	24%	24%	25%	25%
Premium on share capital	15%	5%	6%	6%	6%	6%
Retained Earnings						
Appropriated – legal reserve	1%	2%	2%	2%	2%	2%
Unappropriated	13%	14%	13%	9%	8%	6%
Other components of equity	8%	0%	0%	0%	0%	0%
Equity attribuable to	45%	41%	45%	41%	41%	40%
Non-controlling interests	15%	6%	5%	5%	5%	6%
Total Shareholders' Equity	61%	47%	50%	46%	47%	45%
Total Liabilities and Shareholders' Equity	100%	100%	100%	100%	100%	100%

2.1.3 Growth analysis

Table 2.3 Growth analysis

Historical Financial Statement for BCH

Income Statement (Million Baht)	2017 CMS	CAGR	2017	2016	2015	2014	2013
Revenue							
Revenues from sales	100%	9%	11%	13%	9%	13%	5%
Other incomes	1%	2%	8%	15%	6%	-15%	45%
Total Revenues	101%	9%	11%	13%	9%	12%	6%
Expenses							
Cost of hospital operations	67%	9%	9%	12%	9%	15%	17%
Distribution costs	2%	29%	37%	36%	-12%	119%	76%
Administrative expenses	12%	8%	12%	-5%	22%	14%	28%
Total expenses	80%	9%	10%	10%	10%	16%	19%
Share of profit of investment in associate	0%	0%	-30%	-54%	0%	0%	0%
Profit (loss) before finance costs and	71 71 5						
income tax expenses	21%	0%	-30%	-54%	0%	0%	0%
Finance costs	2%	0%	-16%	-1%	2%	33%	62%
Profit (loss) before income tax expenses	19%	9%	17%	29%	2%	-1%	-26%
Income tax expense	4%	5%	30%	20%	9%	-10%	-43%
Net profit (loss)	15%	9%	20%	39%	0%	- 7%	-30%

Historical Financial Statement for BCH

	_ <u> </u>						
Balance Sheet (Million Baht)	2017 CMS	CAGR	2017	2016	2015	2014	2013
Assets							
Cash and Marketable Securities	16%	10%	204%	-16%	32%	-53%	49%
Accounts Receivable	8%	7%	6%	-7%	-2%	45%	-5%
Inventories	2%	5%	5%	3%	6%	9%	16%
Other Current Assets	0%	-8%	-83%	1%	28%	212%	154%
Total Current Assets	27%	8%	74%	-9%	11%	-15%	22%
Restricted deposits	0%	-54%	1%	-06%	-51%	2%	2%
Investment in associate	0%	0%	-2%	4%	170%	0%	0%
Investment in subsidiaries	0%	0%	0%	0%	0%	0%	0%
Other long-term investments	0%	79%	11%	2%		1973%	0%
Long-term loan to related party	0%	0%		-50%	0%	0%	0%
Investment properties	8%	0%	46%	0%	0%	0%	0%
Property, Plant, and equipment, Net	61%	1%	5%	3%	4%	-7%	49%
Goodwill	3%	10%	0%	0%	63%	0%	29%
Intangible assets	1%	17%	0%	17%	39%	31%	16%
Deferred tax assets	0%	4%	1%	-24%	13%	43%	21%
Other non-current assets	0%	12%	-6%	0%	-50%	279%	92%
Total Non-Current Assets	73%	4%		2%	5%	4%	48%
	0%	0%	0%	0%	0%	0%	0%
Total Assets	100%	5%	20%	0%	6%	0%	41%

Table 2.3 Growth analysis (cont.)

Liabilities and Shareholders' Equity	2017 CMS	CAGR	2017	2016	2015	2014	2013
Short-term borrowings from financial institution	1%	-25%	88%	-93%	64%	12%	29%
Trade accounts payable	4%	3%	11%	16%	5%	-15%	44%
Payables for hospital equipment and medical ins	1%	-5%	123%	-18%	-12%	-51%	5%
Other payables	0%	0%	0%	0%	0%	0%	0%
Short-term borrowing from related party	0%	0%	0%	0%	0%	0%	0%
Current portion of long-term loans from financia	0%	-100%	0%	-100%	9%	-22%	-91%
Current portion of debentures	8%	0%	-33%	88%	0%	0%	0%
Current portion of finance lease liabilities	0%	-100%	-100%	-79%	-8%	-7%	624%
Current income tax payable	1%	13%	83%	4%	3%	-6%	-52%
Accrued expenses	3%	2%	-3%	-2%	8%	5%	54%
Deferred income	0%	-19%	-66%	-6%	8%	-3%	4%
Other current liabilities	0%	-12%	-14%	-31%	-35%	38%	139%
Total Current Liabilities	18%	5%	-13%	-14%	69%	-1%	18%
Long-term borrowings from financial institutions	15%	108%	0%	-100%	-58%	-48%	-97%
Debentures	20%	-5%	0%	0%	-24%	0%	0%
Finance lease liabilities	0%	-100%	0%	-100%	-83%	-45%	621%
Non-current provision for employee benefit	1%	8%	18%	5%	14%	3%	12%
Other non-current liabilities	0%	-19%	83%	2%	-3 5 %	-72%	43%
Total Non-Current Liabilities	35%	40/0	72%	-1%	-25%	-4%	142%
Total Liabilities	53%	4%	29%	-8%	7%	-3%	80%
Paid-In Capital	20%	0%	0%	0%	0%	0%	25%
Premium on share capital	5%	0%	0%	0%	0%	0%	0%
Retained Earnings	0%	0%	0%	0%	0%	0%	0%
Appropriated – legal reserve	2%	2%	0%	0%	0%	9%	15%
Unappropriated	14%	25%	32%	41%	30%	27%	-25%
Other components of equity	0%	0%	118%	-4%	75%	0%	0%
Total Shareholders' Equity	41%	6%	9%	9%	5%	4%	9%
Non-controlling interests	6%	4%	25%	2%	6%	-9%	37%
Total Liabilities and Shareholders' Equit		5%	11%	8%	5%	3%	12%

2.2 Information

2.2.1 Business Structure



Figure 2.1 Shareholding Structure of the company

2.2.2 Major shareholders

Shareholders

Ten major shareholders as at 31 August 2017*

List of the Company's major shareholders and proportion of shareholding from paid-up capital shown in Book of shareholders' registration as follows;

Rank	Name of Shareholders	Number of Shares	Percentage
1	Mr.Chalerm Harnphanich	813,750,000	32.63
2	Mrs.Somporn Harnphanich	183,750,000	7.37
3	SOCIAL SECURITY OFFICE	143,472,000	5.75
4	THAI NVDR CO., LTD.	112,700,769	4.52
5	THE BANK OF NEW YORK MELLON	90,000,000	3.61
6	Mr.Kantaporn Harnphanich	83,000,000	3.33
7	Ms.Pornluck Hamphanich	83,000,000	3.33
8	Ms.Pornsuda Harnphanich	83,000,000	3.33
9	Mr.Paiboon Seriwiwattana	26,653,700	1.07
10	N.C.B.TRUST LIMITED-NORGES BANK 11	22,959,700	0.92
	Total	1,642,286,169	65.86

Figure 2.2 Shareholders

2.2.3 Management and organizational chart




Figure 2.3 Organization chart

2.2.4 Patients referral network




Figure 2.4 Patients referral network

REFERENCES

Research: Hospital valuation in emerging countries by Tsuyoshi Segawa submitted to THE MIT SLOAN SCHOOL OF MANAGEMENT (MIT)

HEALTH AND WELLNESS IN THAILAND from Euromonitor International June 2018 https://market.sec.or.th/public/idisc/th

http://www.thaibma.or.th/EN/Market/YieldCurve/Government.aspx

http://pages.stern.nyu.edu/~adamodar/New_Home_Page/datafile/ctryprem.html

http://www.bangkokchainhospital.com/en/site/home

https://data.worldbank.org/indicator/NY.GDP.MKTP.KD.ZG?locations

http://www.bangkokbiznews.com/news/detail/786471

https://www.verywellhealth.com/primary-secondary-tertiary-and-quaternary-care-primary-secondary-tertiary-and-quaternary-care-primary-secondary-tertiary-and-quaternary-care-primary-secondary-tertiary-and-quaternary-care-primary-secondary-tertiary-and-quaternary-care-primary-secondary-tertiary-and-quaternary-care-primary-secondary-tertiary-and-quaternary-care-primary-secondary-tertiary-and-quaternary-care-primary-secondary-tertiary-and-quaternary-care-primary-secondary-tertiary-and-quaternary-care-primary-secondary-tertiary-and-quaternary-care-primary-secondary-tertiary-and-quaternary-care-primary-secondary-tertiary-and-quaternary-care-primary-secondary-tertiary-and-quaternary-care-primary-secondary-tertiary-and-quaternary-care-primary-secondary-tertiary-and-quaternary-care-primary-secondary-tertiary-and-quaternary-secondary-tertiary-and-quaternary-secondary-tertiary-and-quaternary-secondary-tertiary-and-quaternary-secondary-tertiary-and-quaternary-secondary-tertiary-and-quaternary-secondary-tertiary-and-quaternary-secondary-tertiary-and-quaternary-secondary-tertiary-and-quaternary-secondary-tertiary-and-quaternary-secondary-sec

2615354

https://www.vibhavadi.com/investor/en/

http://investor.bangkokhospital.com/en/downloads/presentations-and-webcasts

http://investor.bumrungrad.com/slides.html

http://economists-pick-research.hktdc.com/business-news/article/Research-Articles/

ASEAN-in-Focus-The-Thai-ConsumerMarket/rp/en/1/1X000000/1X0A8

YMK.htm

www.willistowerswatson.com/en-TH/industries